

Healthy Future Report 2025

teva





Healthy Future

We are proud to share our 2025 Healthy Future Report, which sets out our progress on our Healthy Future sustainability strategy. It encompasses our approach to promoting healthy people, a healthy planet and a healthy business. Healthy Future builds on our Pivot to Growth strategy.



Front cover: From left. Ema Vukelić, Lead Pilot Engineer Scientist, in her Teva R&D lab in Croatia, developing a new active pharmaceutical ingredient molecule. Former Breast Cancer International (BCI) patient, Raheemah Quaye, is now working with the Teva-funded BCI program in Ghana, and Paul Bloching, Critical Systems Mechanic, taking a wastewater sample at a Teva site in Germany.

Inside this Report

01

Introduction

A Letter from our Chairman and President and CEO	2
2025 Sustainability Highlights	3
About Teva	4
Strategic Framework	5
Our Social and Economic Impact	7
Sustainability at Teva	9

02

Healthy People

Health Equity and Access to Medicines	16
Patient Safety and Quality	28
Inclusion and Diversity	33
Employee Health, Safety and Well-being	36
Healthy People: Additional Highlights	38

03

Healthy Planet

Managing our Environmental Impact	40
Climate Action and Resilience	42
Pharmaceuticals in the Environment	48
Product Sustainability	51
Healthy Planet: Additional Highlights	52

04

Healthy Business

Ethics and Integrity	56
Sustainable Procurement	60

05

Disclosures

Disclosures	64
-------------	----

06

About This Report

Independent Assurance Statement	67
Cautionary Note Regarding Forward-looking Statements	72

A Letter from our Chairman and President and CEO

At Teva, building a healthy future is not a separate initiative – it is embedded in how we do business every day.

It strengthens our resilience, guides our decisions, and ensures we continue to deliver on our purpose: we are all in for better health. Together, our 'Pivot to Growth' business strategy and our 'Healthy Future' sustainability strategy create a powerful foundation for long-term impact.

In 2025, we delivered strong, measurable progress across our sustainability priorities. We believe that tracking our impact is essential – it keeps us accountable and ensures our efforts are focused on what truly matters.

Among the achievements we are particularly proud of:

- We exceeded all three targets tied to our sustainability-linked bonds – an accomplishment that reflects the deep connection between our sustainability performance and our financial strategy. As a result, we expanded access to medicines for some of the world's most

underserved populations, while also significantly reducing our environmental footprint.

- Our access to medicine initiatives reached 7.9 million patients through product donations, including 204,000 via our eight strategic access programs. In parallel, our health system strengthening and capacity-building efforts supported an additional ~400,000 people, helping build more resilient and equitable healthcare systems.
- Our generic medicines continued to play a critical role in improving affordability and access, generating \$36.4 billion in savings for healthcare systems and patients across over 20 countries – ensuring that more patients receive high-quality treatment at lower cost.



- We made strong progress on climate action, reducing our Scope 1 and 2 greenhouse gas emissions by 39% beyond our interim target of 25% since our 2019 baseline. This achievement reflects the focus and discipline of our decarbonization efforts and keeps us firmly on track toward our long-term goals.
- Recognizing the powerful role that sustainable product design plays across the life cycle of our medicines, we introduced Product Sustainability as a new focus area within our Healthy Future strategy – benefiting both the planet and our business.
- Our commitment to integrity remains unwavering. Once again, over 99% of our active employees completed their assigned compliance and ethics training, reinforcing a culture grounded in accountability, transparency and trust.

As we continue to execute our strategy and accelerate the growth of our business, we expand our ability to create positive impact – for patients, for communities, and for the environment. This connection between performance and purpose is what drives us forward.

We are grateful to our employees and partners for their dedication and collaboration throughout the year. Together, we are helping shape a healthy future.

We invite you to explore our Healthy Future Report to learn more about how we are contributing to the well-being of people, the planet and our business.

Richard Francis
President and CEO

Dr. Sol J. Barer
Chairman of the Board of Directors

2025 Sustainability Highlights



7.9 million
people reached through our global product donations

Breast Care International program in Ghana

Healthy People

399,000

beneficiaries of our health system-strengthening and capacity-building programs

50%

of Teva managers are women

[Read more on page 15](#)



39%
reduction in greenhouse gas emissions from our operations since 2019, exceeding our 25% target for 2025

Teva employees in Germany

Healthy Planet

60%

of our electricity used comes from renewable sources

73%

of our applicable sites have achieved safe discharge levels of antimicrobials

[Read more on page 39](#)



>99%
of our active employees completed their assigned compliance and ethics trainings in 2025

Teva employees in the Netherlands

Healthy Business

100%

of all our submitted third-party representative business partners evaluated through Teva's due diligence tool (RiskMate)

66%

of our significant suppliers (by spend) have undergone sustainability performance evaluations

[Read more on page 55](#)

Our Ratings Performance 2025

Organization	Performance	Industry ranking
Sustainalytics	📈 15.6 low risk	📈 Top 3%
MSCI	📈 A 5.9	
ISS ESG	➡ B-	➡ Top 10%
S&P Global	📈 55	📈 Top 12%
EcoVadis	📈 76	➡ Top 4%
CDP	➡ A- (Climate) 📈 A- (Water)	

- 📈 Improvement vs. 2024
- ➡ Consistent vs. 2024 (+/- 1%)

ESG rating scores are accurate as of March 23, 2026; EcoVadis as of December 16, 2025. For MSCI, the numbers are related to the industry-adjusted score.



We are headquartered in Israel, where we were founded 125 years ago

tevapharm.com/our-company

Teva employees at our Davie site, Florida, USA during the visit of our CEO, Richard Francis

Our Business

Teva is a leading biopharmaceutical company, enabled by a world-class generics business, reaching millions of people each day across

57 markets

tevapharm.com/product-focus

Global Reach

46 manufacturing facilities

21 research and development sites

66 billion tablets and capsules produced

600 million sterile units produced

Supply Chain

>41,000 suppliers we work with

Our People

~34,000 global workforce (including contingent workers)

Leadership

Our Board of Directors, chaired by Dr. Sol J. Barer, comprises 12 members (all independent, aside from President and CEO). Our company is led by our President and CEO, Richard Francis.

Trading

Public

Teva is publicly traded on the New York Stock Exchange (NYSE:TEVA) and the Tel Aviv Stock Exchange (TASE:TEVA).

Strategic Framework

Guided by our values...



Inspired by our purpose...

We are all in for better health

We: unite our employees as one – regardless of business function or geography – for one common goal.

All in: means all of us, but also all of our energy, ideas, resource and innovation power. We are truly “giving it our all”.

Better: brings soul and accountability to how we approach the world – “better” emotionally connotes a measure of impact.

Health: connects business objectives to our broader purpose and includes the health of society, communities and the economy.

We are dedicated to delivering better health through our business strategy...

Pivot to Growth:

- Deliver on growth engines
 - Step up innovation
 - Sustain generics powerhouse
 - Focus the business
- [Read more on page 6](#)

...and a better world through our vision for a Healthy Future

Healthy People

Improving the well-being of people and society

[Read more on page 15](#)

Healthy Planet

Safeguarding our planet

[Read more on page 39](#)

Healthy business

Leading our business the right way

[Read more on page 55](#)

Strategic Framework continued

Our Pivot to Growth Strategy

All numbers included here relate to 2025 unless otherwise stated.

Deliver on Growth Engines

We will continue to fuel our key growth engines by strengthening and expanding them across core markets to address critical unmet needs.

192
medicines in our innovative portfolio

15
new innovative medicine marketing authorizations

10
medicines in our biosimilar portfolio

2
biosimilar medicines launched



Teva employees in our São Paulo labs, Brazil

Step up Innovation

We have reengineered our R&D engine to focus on proven science and capital-efficient development, accelerating our most promising late-stage assets with innovation for patients at the core.

12
innovative medicines in development in pipeline*; of those, 6 developed in partnerships

15
biosimilar medicines in development in pipeline*; of those, 9 developed in partnerships

*Pipeline as of January 28, 2026



Teva R&D employees at our Netanya site in Israel

Sustain Generics Powerhouse

We leverage our world-class generics business to deliver accessible medicines to millions of patients worldwide, while creating greater value through a more selective and focused portfolio.

1,760
medicines in our generic portfolio

97
generic medicine product launches, 33 of which were complex generics and 26 were in low and middle-income countries (LMICs)

849
new generic medicine marketing authorizations, including 28 in LMICs

180
generic medicines in our pipeline, including 8 antibiotics and antifungals



Teva employees, working on the production line at our site in Maipu, Chile

Focus the Business

We are modernizing our organization by simplifying operations, scaling lean manufacturing, and increasing agility, including preparing Teva API (TAPI) as a standalone business for future divestment.

323
generic APIs in our portfolio

7
innovative APIs in our portfolio



Teva employees meeting in Maipu, Chile

Our Social and Economic Impact

As a global leader in biopharmaceuticals, we don't just deliver medicines, we help fuel economic growth in every market we serve, supporting jobs and income through our operations and broader value chain.

At the same time, our broad generics portfolio delivers substantial savings for healthcare systems, expanding patient access to essential medicines and strengthening the long-term sustainability of care.

In 2025, we conducted, for the fifth time, an assessment to quantify the value we provide to the economy and our impacts, in terms of savings from generic medicines, contributions to the labor market and economic output. The assessment of generic savings covers 21 countries and, for other economic impact indicators, 26 countries.

Generic Medicine Savings¹

Our generic medicines generate savings for healthcare systems and help patients access treatments at lower costs, without compromising quality. These savings can positively impact family healthcare budgets by lowering necessary medicines costs.

Teva's generic medicines contributed to

\$36.4 billion²

in savings across 21 countries,

including:

\$31.4 billion³

in the USA

\$3.2 billion


in 14 countries in Teva's Europe region

\$1.8 billion

in 6 countries in Teva's International Markets region

Savings from Teva's Generic Medicines (\$ Millions)

- United States
- Europe
- International Markets



¹ Savings refers to cost savings compared with the originator product, calculated based on the price difference between the originator's product and Teva's generic product.

² This analysis covers 21 countries which represent 84% of total generic revenue (excluding: biosimilars, over-the-counter and Medis). External data used to calculate generic medicine savings are not available for UK, India, Ireland, China and Israel.

³ This figure uses an estimate for 2025 generic savings in the USA based on the 2024 Association for Accessible Medicines reported savings, assuming an average yearly generic savings increase of 8.0% for 2025 and Teva's generic market share of 6.5% for Moving Annual Total (MAT) December 2025. Click [here](#) for an explanation of our Economic Impact and Generic Medicine Savings methodology.

Our Social and Economic Impact continued

Social and Economic Impact Around the World

We recognize our tremendous opportunity – and responsibility – to improve lives and deliver lasting societal impact. Applying a shared-value mindset, we seek to create business value, while also benefiting society. Our spending and income, both directly and indirectly through our supply chain,

initiate a production cycle that creates jobs and contributes to improving the economy and communities.

Country	GDP (\$M)	Jobs	Labor Income (\$M)
United States			
United States	9,315	38,808	2,822
Europe			
Bulgaria	274	9,863	141
Croatia	610	15,322	349
Czech Republic	471	7,850	229
Denmark	81	311	17
France	380	2,359	151
Germany	1,314	10,246	584
Hungary	716	14,394	325
Ireland	626	4,766	223
Italy	494	4,999	200
Netherlands	538	7,315	334
Poland	407	4,630	126
Romania	110	1,860	49

Country	GDP (\$M)	Jobs	Labor Income (\$M)
Spain	436	4,485	196
Sweden	178	789	38
Switzerland	933	12,669	449
United Kingdom	555	4,530	255

International Markets

Australia	100	769	40
Canada	433	5,277	211
Chile	225	3,079	83
China	25	1,204	16
India	490	31,820	154
Israel	3,986	39,859	2,001
Mexico	172	3,780	78
Russia	431	7,917	137
Ukraine	90	1,090	28



Teva employees at our Ridings Point depot, UK

Teva's direct and indirect economic activity in 26 countries assessed:

240,000

jobs supported (in full-time equivalents or FTEs)

\$9.2 billion

generated in labor income, a measure of aggregate worker wages

Note: This analysis covers 26 countries with 29,937 FTEs (representing around 93% of Teva's global workforce of 32,313 FTEs). See the [2025 Healthy Future Report Disclosures](#) for further information and restatement of 2023 and 2024 data. Click [here](#) for an explanation of our Economic Impact and Generic Medicine Savings methodology.

Sustainability at Teva

Our Strategy


As a global biopharmaceutical company, we believe that championing sustainability today means creating a positive impact and building a healthy future for generations to come. It reflects our purpose in practice: we are all in for better health.

We are dedicated to doing business responsibly and leveraging our footprint, resources and skills to improve health outcomes for all through our extensive portfolio and pipeline of medicines.

This includes taking concrete action on health equity and access to medicines for underserved populations around the world; protecting patients and our employees by ensuring their health and safety; creating a culture where all employees feel welcome; combating global challenges such as climate change, reducing pollution and protecting the environment; building trust with stakeholders through high standards of ethics and integrity and extending our positive impact over our supply chain.

Our Healthy Future strategy is a continuation of our sustainability journey and encompasses all that we do to promote healthy people, a healthy planet and a healthy business.

Aligned with our Pivot to Growth strategy, Healthy Future outlines a clear path for advancing our performance through enhanced actions and transparency across the topics that matter most to Teva and our stakeholders, supported by ambitious, measurable targets.



Teva employees participating in a well-being month activity in Amsterdam, the Netherlands

Sustainability at Teva continued

Our Priorities

We focus on what matters most to our business. This, and the expectations of our stakeholders, guides our Healthy Future strategy and ensures alignment with our Pivot to Growth strategy.

We regularly engage with stakeholders through processes, such as our Double Materiality Assessment (DMA), to identify our main impacts on society and the environment, and the sustainability-related risks and opportunities that are most relevant to our business.

2025 represented the first annual review cycle and update of our 2024 DMA. The update largely corroborated the previous results, and served as an opportunity to implement newly-published formal guidance on performing DMAs. This review resulted in seven material topics, related to 14 material impacts, risks and opportunities.


The 2025 identified material topics are:

- Health Equity and Access to Medicines*
- Patient Safety and Quality;
- Employee Health, Safety and Well-being;
- Inclusion and Diversity*;
- Climate Action and Resilience*;
- Pharmaceuticals in the Environment (PIE)*;
- Ethics and Integrity*.

Healthy Future Focus Areas

Our selected Healthy Future focus areas are those that generally go beyond our core fundamentals, and require the most attention to advance sustainability at Teva, creating long-term value. In addition to the five material topics highlighted in the list to the left, we have included two non-DMA determined topics, Sustainable Procurement and Product Sustainability, as they cut across many areas of sustainability and support our efforts in mitigating other negative environmental and social impacts.

We recognize the interdependence of all these focus areas and the importance of managing them in a coordinated way, to contribute to a healthy future. For most of the focus areas, we have ambitious targets to hold us accountable and track our progress. We report on our actions and performance across our focus areas and the other material topics in this Report in our [Healthy Future Report Disclosures](#).




Note: For more information on the DMA methodology in our [Healthy Future Report Disclosures](#), see pages 20–22. The material topic formally titled "Health equity and access to medicines" may be referenced in this report as "Health equity and access". Both terms refer to the same material topic.
* These five material topics are included as focus areas within our Healthy Future strategy.

Sustainability at Teva continued

Our Value Chain

Teva is a leading innovative biopharmaceutical company, enabled by our world-class generics business, to reliably deliver medicines to patients worldwide. We carefully monitor the impacts, risks and opportunities generated by our engagements and activities with stakeholders across our value chain.





Sustainability at Teva continued

Governance

Governance is about good management, accountability, systematic ways of working and ownership. We value transparency and continuously seek to improve our business practices, guided by our [Corporate Governance and Policy Documents](#). Our Healthy Future governance model encapsulates responsibility for our sustainability strategy and activities. All our Executive Management members have relevant Healthy Future sustainability goals across various topics (e.g. greenhouse gas emissions, health equity and access to medicines, and ethics and integrity) tied to their compensation (annual bonuses). This drives accountability and progress. We also embed sustainability into our processes, decisions and actions.

In 2025, seven updates on Sustainability were provided to the board and its relevant committees.



Sustainability at Teva continued

Fostering a Culture of Sustainability

We share our sustainability commitments, actions and progress regularly and transparently, raising awareness of our many initiatives with all our stakeholders.

Shaped by our belief that real change is driven by focus, purpose, action and engagement, we want to create a culture of transparency and accountability. By openly sharing targets, processes and progress, we aim to build trust and credibility with all our stakeholders.

Sustainability is everyone’s responsibility at Teva. We encourage this by:

- collaborating to address global challenges, improve health, make a positive environmental and social impact, and strengthen our resilience;
- empowering our employees through our sustainability strategy to adopt and advocate for sustainable and ethical practices;
- educating through internal articles, webinars, screensavers, teams backgrounds, surveys, challenges, videos, vlogs and more; and
- celebrating teams that innovate and advance sustainability in their daily work, so our employees can become ambassadors for real-world change.



At Teva, accountability fuels action: by setting concrete targets, tracking progress and sharing it openly, we build trust, empower our people, and make sustainability a shared responsibility that drives positive change globally.

Employees participating in Teva’s Go Green Together initiative, Hungary

Sustainability at Teva continued

Sustainable Finance

2025 marked the target year for measuring our performance against goals associated with our sustainability-linked bonds, and we are proud to announce that we surpassed all of them.

We have tied our commitments and progress in priority areas, such as climate action and resilience, health equity and access to medicines, to our business strategy through sustainable finance instruments. Teva's combined sustainability-linked bond (SLB) issuances in 2021 and 2023 totaled ~\$7.5 billion, making us the largest issuer in the pharmaceutical sector and the second largest corporate SLB issuer in the world.


Our syndicated sustainability-linked revolving credit facility (RCF)¹ is scheduled to continue until 2027, providing a continued commitment to making regulatory submissions of essential medicines in LMICs.

Our sustainability-linked bonds (SLBs)

~\$7.5 billion

combined SLBs issued, including \$5bn issued in 2021 and \$2.49bn issued in 2023

Over their respective lifespans, our SLB goals enabled meaningful social and environmental impact:



¹ Entered into in 2022, amended in 2023, 2024 and 2025.

Healthy People

In this Section

Health Equity and Access to Medicines	16
Patient Safety and Quality	28
Inclusion and Diversity	33
Employee Health, Safety and Well-being	36
Healthy People: Additional highlights	38

7.9 million


patients reached through all *medicine donations* in 2025

399,000

beneficiaries reached through *health systems strengthening* and capacity-building initiatives in 2025

35%

of *Vice President level and above* roles were held by *women* at Teva in 2025



Former BCI patient Raheemah Quaye now works with the Teva-funded BCI program in Ghana, raising awareness and counseling newly diagnosed breast cancer patients

“What once brought me fear now fuels my purpose. Today, my story gives hope to other women who once felt alone and hopeless in their cancer journey.”

Raheemah Quaye
Breast cancer survivor, advocate and counselor at Breast Care International (BCI)

[Read more on page 16](#)

Health Equity and Access to Medicines


At Teva, we are all in for better health. Increasing access to quality medicines and strengthening healthcare systems is fundamental to improving the health of patients and the success of our business.

We develop and supply high-quality generic and biosimilar medicines that reach millions of patients across the globe each day, to achieve our purpose – being “all in for better health”. One of the ways we do this is by working to ensure access to affordable medicines for underserved populations, and addressing unmet health needs across the globe through our innovative portfolio.

Our patient-centric approach to health equity and access to medicines takes shape across the life cycle of all our products, and is grounded in the core principle that every individual – regardless of geography or circumstance – deserves access to healthcare.

While global demand for medicines continues to rise, around one-third of the world’s population lacks access to medicines, vaccines, diagnostic tools and other essential treatments¹. Underserved populations and those living in under-resourced communities across the globe are often unable to obtain the treatments they need as a result of a multitude of complex barriers.

Our Health Equity and Access to Medicines strategy and Pivot to Growth business strategy are aligned to drive progress and meet our business ambitions, while making a significant social impact.

 Watch how Teva is making a difference to the lives of children with cancer in East Africa through the Global HOPE program.

Governance

Our Health Equity and Access to Medicines initiatives are approved by the responsible Executive Managers. Our Board of Directors’ Compliance Committee is kept informed on the progress of these initiatives as part of their Sustainability oversight.

Our dedicated Health Equity and Access to Medicines Steering Committee is chaired by the Senior Vice President, Global Head of Sustainability and includes the participation of other senior managers. The Committee advises on our Access to Medicines initiatives on a strategic level.

Additionally, Teva’s access activities are shared with the Sustainability Steering Committee, chaired by the Chief Executive Officer. Our Access to Medicines targets are also part of the Executive Management variable remuneration.

Guiding Document

 [Teva’s Position to Access to Medicines](#)

Increasing access to medicines in 2025

Through our Business

1,760 generic medicines in our portfolio	9 regulatory submissions in low and middle-income countries (LMICs) on the WHO Essential Medicines List (EML) across key TAs
192 innovative medicines in our portfolio	849 new generic medicine marketing authorizations, including 28 in LMICs
10 biosimilar medicines in our portfolio	

Beyond our Business

361.4m total doses (worth over \$637.1m) ² donated to patients ³	21.5m doses provided through our access programs, including 0.5m doses (worth over \$9m) ² to LMICs on the WHO EML across key TAs
651,800 patients reached by Global Health Tenders	204,000 patients reached through 8 access programs

1 Essential Medicines and Pharmaceutical Policies. Source: World Health Organization, <https://www.emro.who.int/essential-medicines/strategy-access/>
 2 Worth of medicine provided is represented in wholesale acquisition cost (WAC) or the local market equivalent.
 3 Inclusive of donations made through the Teva Cares Foundation.

Health Equity and Access to Medicines continued

Progress on Targets

● Achieved ● In progress ● New target


Subtopic	Targets	Progress	Status
Health Equity and Access to Medicines			
Registration of Products (Regulatory Submissions)	Increase the cumulative number of new regulatory submissions in low- and middle-income countries (LMICs) on the WHO Essential Medicines List (EML) across six key therapeutic areas (TAs) ¹ by 150% from 2022–2025 (vs. 2017–2020) ²	83 submissions cumulative (increased by 177% vs. 2017–2020)	●
	New target: Increase the cumulative number of new regulatory submissions in low- and middle-income countries (LMICs) on the WHO Essential Medicines List (EML) across six key therapeutic areas (TAs) ¹ by 220% from 2022–2027 (vs. 2017–2020) ³	83 submissions cumulative (increased by 177% vs. 2017–2020)	●
Access Programs and Product Volumes	Increase access to medicines programs' product volume by 150% in 2025 (vs. 2020) through four access to medicines programs, including donations and social business in LMICs on WHO's EML across six key TAs ^{1,2}	6.7m single unit doses provided (increased by 1242% vs. 2020)	●
Patient Reach	New target: Increase the cumulative number of underserved patients reached with products through access initiatives to at least 1 million from 2023–2029	537,746 cumulative patients reached	●
Health System Strengthening and Capacity Building	Increase the cumulative number of beneficiaries of health system-strengthening and capacity-building initiatives in support of underserved populations by 200% by 2026 (vs. cumulative 2022–2023 baseline)	470,709 beneficiaries reached (increased by 1533% vs. 2022–2023)	●
Patient Centricity	Incorporate a patient-centric approach in 100% of clinical trials for innovative products by 2030, which will help enable more equitable access to medicines	100% of clinical trials for innovative products initiated in 2025 incorporated a patient-centric approach	●

1 Therapeutic areas for submissions include: cardiovascular diseases, pediatric oncology, respiratory diseases, diabetes, mental health and pain/palliative care. Therapeutic areas for volumes include: cardiovascular diseases, adult and pediatric oncology, respiratory diseases, diabetes, mental health and pain/palliative care.
 2 Target is part of sustainability-linked bond.
 3 Target is related to syndicated sustainability-linked revolving credit facility.


To reinforce our dedication and to hold ourselves accountable to advancing health equity, two of our access commitments were linked to our financial strategy through sustainability-linked finance instruments, including sustainability-linked bonds (SLBs).

Sustainability Linked Bond Access Performance

Product Volume in LMICs Across Six Key TA Access Programs (millions of doses)



Cumulative New Regulatory Submissions in LMICs Across Six Key TAs



* Not counted toward target


Health Equity and Access to Medicines continued

Our Approach to Health Equity and Access to Medicines

We take a holistic, strategic and proactive approach to Health Equity and Access to Medicines to increase global reach and impact through:

- developing and supplying **quality and affordable generic and biosimilar medicines**, that reach **millions of patients** across the globe each day;
- providing medicines to **underserved populations**;
- addressing **emergencies and disasters** quickly and efficiently;
- strengthening healthcare systems and building local capacity to **improve health systems and services**;
- increasing access to our products in **low- and middle-income countries (LMICs)** through **product registration submissions**; and
- including access considerations, such as a **patient-centric approach**, within our **product development**.

Teva's Health Equity and Access to Medicines Pillars



1 Source: IQVIA MIDAS MAT Q4 2025; Analysis of 38 countries.

A Unique Portfolio of Medicines

We increase access to quality medicine through our products: our innovative medicines help address the unmet health needs of a diverse range of patients, while our generic and biosimilar medicines offer more affordable options and reach more patients across the globe.

Our portfolio of generic medicines covers 56% of treatments on WHO's Essential Medicines List of important drugs, which address key healthcare needs across the globe, including¹:

- 59% of cardiovascular treatments;
- 65% of pain treatments;
- 61% of mental health treatments;
- 44% of anti-infective treatments;
- 59% of cancer treatments;
- 32% of respiratory treatments; and
- 29% of diabetes treatments.

Case study

Socioeconomic Value Through our Access Programs

Teva commissioned a pilot assessment of the clinical and socioeconomic impacts of its 2025 medicine donations to the **Breast Care International (BCI)** program in Ghana (see [page 20](#)). Ghana records over 4,000 new breast cancer cases each year, with mortality rates nearing 50%.

Using health economic modeling and a value-chain approach, the analysis measured health gains in QALYs (quality-adjusted life years) and translated them into economic value through impacts on paid and unpaid labor. In 2025, Teva's donations to BCI in Ghana enabled treatment for 1,040 patients, generating approximately \$1:4, meaning that for every \$1 invested in this program, there is a resulting \$4 in societal value. Additionally, this program generated 178 QALYs in 2025, equivalent to around two additional months of quality-adjusted life per patient, which reflects the aggregate impact of the program as a bundled intervention. Most benefits were realized among women aged 20–59.

This assessment confirms that Teva's support for the BCI program delivers meaningful health and societal value for Ghana, while contributing to health as a driver for growth.

Click [here](#) for an explanation of this BCI assessment methodology.

Health Equity and Access to Medicines continued

Improving Health Impact

We are committed to maximizing our positive impact by prioritizing those most in need.

Our eight¹ active Access to Medicines programs on [pages 20 and 21](#) provide treatments to underserved populations worldwide via customized, localized models conducted with partner organizations, tailored to meet specific national health challenges. By spearheading these initiatives and aligning our strategies with global health priorities, we ensure that our programs are conducted according to best practices, while advancing access to medicines and strengthening local healthcare systems and building capacity worldwide.

Our programs consist of product donations or social business initiatives, and each program supports global health needs by reaching underserved communities.

- In 2025, we donated **19.4 million doses** of medicines through our strategic access initiatives, worth **\$29.0 million**². Of these, **6.7 million doses** were donated through programs included in our SLB target.
- Through our social business programs, we sell our products at a low cost to partners, who then distribute to underserved patients, making a sustainable, positive impact, while supporting our business. In 2025, we supplied more than **2.1 million doses** of medicines through such channels.

To execute our programs, we partner with trusted organizations that know the needs of local communities, are familiar with local health systems, and understand and can implement appropriate patient treatment plans directly with healthcare providers.

Increasing Product Registration in LMICs

In order to expand access to our medicines in the most hard-to-reach places, we are expanding our product submission and registration in LMICs, an important milestone to getting a medicine approved by the relevant authorities in a new market.

We surpassed our target of 75 cumulative LMIC submissions in 2025, having made **83 submissions** since 2022. Our commitment to increase product submissions for a specifically-selected pool of products, representing some of the largest unmet needs with the greatest growing burden of disease, supports our systematic approach to access.

Health System Strengthening and Capacity Building

Improving access to medicines requires a holistic approach that addresses the broader determinants of health, including financial, geographic, socioeconomic, cultural and other factors.

True health equity can only be achieved with strong, resilient healthcare systems. Supporting the development and strengthening of healthcare systems is a core pillar of our access strategy. By fostering robust healthcare systems, we can help create the conditions necessary for equitable access to care and improve health outcomes for many more people.

Capacity building is critical for improving healthcare systems, enhancing health literacy and awareness, increasing treatment accessibility through diagnosis and screening, and building trust within local communities. Our health system strengthening and capacity-building initiatives expand healthcare

professionals' skill sets and enhance local capacity to support the health needs of underserved populations.

Having increased the cumulative number of beneficiaries reached through our healthcare and capacity-building initiatives by 1533% (vs. cumulative 2022–2023 baseline), we surpassed our target of a 200% increase one year ahead of time. This significant uptick was due to the strong focus we placed on recognizing barriers to care and creating holistic and impactful programming as a response.

Many of our health system strengthening and capacity-building initiatives are embedded within our Access to Medicines programs, complementing and enhancing their holistic approach to achieving sustainable health outcomes (see [pages 20 and 21](#)). Beyond those, key initiatives we have led or supported in 2025 included, 'A New Day for Sickle Cell Disease' in Uganda and 'Support the Soul' in Israel (see [page 22](#)), as well as palliative care and mental health initiatives in India.



Healthcare professionals at the Boanim Health Clinic pharmacy, Ghana, part of the Breast Care International (BCI) program

1 Four programs are eligible for inclusion in our product volume sustainability-linked bond (SLB) target.
 2 Worth of medicine provided is represented in wholesale acquisition cost (WAC) or the local market equivalent.

Health Equity and Access to Medicines continued

Improving Access to Medicines – Our Eight Access Programs

Working with our trusted partners, our Access Programs focus on getting life-changing Teva products to underserved populations, that would otherwise go without. To complement some of these programs and create a holistic approach for improved health outcomes, we also incorporate health system strengthening and capacity-building attributes. Below we outline the contributions of our access progress in 2025.

Categories key

- Donations
- Social Business
- Health System Strengthening

Global Health Emergencies



Sustainability-linked bond



Through the **Strategic Emergency Stockpile (SES)** program, Teva addresses health emergencies worldwide and supports communities in crisis. With Direct Relief, we provide essential medical supplies for rapid deployment in emergency response efforts, such as South Sudan.

“Thanks to rapid response efforts, cholera hospitalizations in Mayom County have dropped from around 50 cases per day to just one per day.”

Emergency Response Manager, Direct Relief

approximately
8.6 million doses of medicine donated

worth around
\$15.5 million¹

reaching approximately
84,600 patients

Malawi, Uganda, Kenya, Tanzania and Rwanda



Sustainability-linked bond



Through **Global HOPE**, we donate essential drugs and comprehensive care for children with cancer and blood disorders in sub-Saharan Africa. We also sponsor learning modules for local HCPs. We provided formal training for **19 nurses and medical officers**, ultimately allowing for the screening of **1,500 patients**, who would have otherwise gone undiagnosed.

“Through adequate medication and the dedication of health workers, my son Augustine has improved.”

Mr. Kamanga, Augustine’s father

approximately
3.5 million doses of medicine donated

worth around
\$5.3 million¹

reaching approximately
22,500 patients

Ghana



Sustainability-linked bond



With partners **Breast Care International (BCI)** and Direct Relief, we provide early diagnosis and treatment, and local screening, as well as improving information sources in Ghana through our capacity-building efforts. We reached over **30,000 patients and community members** through awareness and screening activities. We also donated lifesaving cancer therapies.

“Teva’s donations provide lifesaving treatment to women and men who otherwise could not afford it.”

Dr. Beatrice Wiafe Addai, President, BCI

approximately
385,000 doses of medicines donated

worth around
\$3.3 million¹

reaching approximately
1,000 patients

USA



Teva donates generic medicines and supports behavioral health services for uninsured and underserved patients, suffering with anxiety or depression, through our **Community Routes: Access to Mental Health Care** program, in partnership with Direct Relief and the National Association of Free & Charitable Clinics. In 2025, Teva committed another \$2 million and announced 11 new grantees across Alabama, Mississippi and Texas. Our capacity-building initiatives included patient screenings, therapy, community events and training for professionals, benefiting over **17,500 patients directly** and a further **39,500 patients indirectly**.

approximately
6.2 million doses of medicines donated

worth around
\$4.1 million¹

reaching approximately
24,500 patients

¹ Worth of medicine provided is represented in wholesale acquisition cost (WAC) or the local market equivalent. Note: “Sustainability-linked bond” (SLB) indicates program eligible to the SLB target.

Health Equity and Access to Medicines continued

Our Eight Access Programs continued

Categories key



Donations



Social Business



Health System Strengthening

Israel



A small margin of the Israeli population struggle to access essential treatments, due to socioeconomic hardship or costly medications not covered by national health or private insurance. Teva works with Friends for Health (Haverim L'Refuah), a local NGO that collects medications and receives donated products to support these underserved patients.

"Our work with Teva demonstrates the power of responsible partnership. Their donations allow us to deliver essential treatments to underserved patients, making a tangible difference in people's lives."

Baruch Liberman, Founder, Haverim L'Refuah

approximately
500,500 doses of medicine donated

worth around
\$560,000¹

reaching approximately
5,400 patients

El Salvador



Sustainability-linked bond

Teva's program with Americares and FUSAL strengthens access to medicines in underserved communities in El Salvador that face barriers to healthcare.

One of the centers benefiting is the Clínica Asistencial Corazón de María. Founded in 1988, it provides primary healthcare and appointments to patients, including families with low incomes. Teva has donated medicines that have ensured continuity of treatment for chronic patients, improving their well-being and reducing the risk of severe complications.

approximately
181,000 doses of medicine donated

worth around
\$189,000¹

reaching approximately
3,800 patients

Spain



Around 1.5 million people in Spain cannot afford prescription medicines and health products for chronic diseases.

In 2025, we continued to help Banco Farmacéutico increase access to underserved populations.

"There are instances when people suddenly become poor, not able to pay for food, to pay the rent, and also medicines. At Banco Farmacéutico, what we want to achieve is that no one needs to choose between health and other expenses."

Alex Brenchat, President of Banco Farmacéutico

approximately
57,000 doses of medicine provided

reaching approximately
1,500 patients

France



Together with Pharmacie Humanitaire Internationale (PHI), we supply medicine to charitable care centers that provide medication, consultations and social services to underserved patients.

"Since 2022, we have benefited from a special partnership with Teva in France, which we renew every year with satisfaction. The recognition we receive from healthcare centers confirms our commitment to our activity and encourages us to always offer them the best quality of service."

Geneviève Kinowski, Pharmacist in charge of PHI

approximately
2.1 million doses of medicine provided

reaching approximately
61,000 patients

¹ Worth of medicine provided is represented in wholesale acquisition cost (WAC) or the local market equivalent.

Note: "Sustainability linked bond" (SLB) indicates program eligible to the SLB target.

Health Equity and Access to Medicines continued

Other Access to Medicines Initiatives

Addressing Emergencies and Disasters

We continuously explore opportunities to support underserved patients and those facing emergencies and disasters, so they can obtain the medicines they need. We work closely with suppliers, partners and healthcare organizations to provide timely medical support in emergencies and disasters, where we can.

For example, during hurricane Melissa in October 2025, Teva donated over **8.8 million doses** of medicines for a vast range of conditions, ranging from diabetes to infectious diseases.

Through our SES program, we work with Direct Relief to provide products for disaster relief efforts worldwide. In January 2025, we donated **10,000 packs** of ibuprofen to manage an mPox outbreak in Sub-Saharan Africa. The kits also supported mPox patients in Liberia and Sierra Leone in May 2025.

USA Inhaler Access Program

As part of our partnership with Direct Relief to make available two generic inhalers free of charge to uninsured patients at free and charitable clinics in the USA, in 2025, we shipped **160,000** inhalers worth over **\$7.2 million** reaching patients at **398 clinics**.

Teva Cares Foundation Patient Assistance Program

Since 2013, the Teva Cares Foundation¹ has provided certain Teva medicines at no cost to patients in the USA who meet specific insurance and income eligibility criteria. In 2025, the Foundation donated medicines worth over **\$136.7million²**.

Other Health System Strengthening Initiatives

Partnering with Texas Children’s Hospital on ‘A New Day for Sickle Cell Disease Initiative’³

Sickle Cell Disease (SCD) is the most common inherited disease in the world; 80% (>500,000) of all children born with SCD annually are African. These children live a brief life; 50%–90% won’t survive to see age five. Affected families typically have multiple children with SCD. Through a multi-pronged approach, we are providing support to SCD communities in sub-Saharan Africa³.

Installing a Reliable and Clean Power Supply for an SCD Clinic:

Caring for children with SCD requires consistent and frequent access to care, making care particularly vulnerable to power-related disruptions. In partnership with Direct Relief’s ‘Power for Health’ initiative, we are modernizing the SCD clinic at the Mulago National Referral Hospital in Kampala, Uganda – the largest public hospital in the country, introducing low-cost, clean energy and strengthening the healthcare system. A newly-designed clean power installation will include customized solar PV and a battery back-up system to power the SCD Clinic, as well as the installation of new LED lighting, new cold-chain refrigeration units, air conditioning and computers. By replacing diesel generators, the site will break even between year three to four of a 25+ year lifespan. From an environmental perspective, replacing diesel generators will save an estimated **35 tCO₂e/year**.

Provision of SCD Testing Kits

We provide point-of-care SCD testing kits to remote populations in Uganda via Texas Children’s Hospital, through the Baylor College of Medicine Children’s Foundation – Uganda. Traditional testing kits are often unavailable or provide answers slowly and inefficiently. We are committed to screening at least **60,000 children** by the end of 2026.

1 Teva Cares Foundation is a separate legal entity funded by Teva.
2 Worth of medicine provided is represented in wholesale acquisition cost (WAC) or the local market equivalent.
3 <https://pubmed.ncbi.nlm.nih.gov/22099364/> and <https://who.int/news-room/fact-sheets/detail/sickle-cell-disease>

Support the Soul in Israel: The Mental Health Crisis After October 7, 2023



Two years after the violent assault of October 7, 2023, citizens in Israel continue to struggle with post-traumatic stress disorder and related issues such as depression, anxiety, sleep disorders and addictions. Since 2023, post-trauma services in Israel have been enhanced, partly due to our Support the Soul program, but there is still plenty to do. Israel needs more professional trauma therapists as the shortage hampers mental health support and recovery. Therapists are also experiencing burnout, as well as dealing with intense personal challenges. Working with partner NGOs, our Support the Soul program trains professional teams, creates safe therapeutic spaces and develops innovative tools and support. Since its inception, Support the Soul has made mental health services more accessible, by strengthening two resilience centers, training and supervising around **1,542 professional therapists** and equipping up to **9,288 first responders** with resilience tools. Overall, the program benefited nearly **20,000 people** directly, and a **further 147,580** indirectly. The program also supports a mental-health technology accelerator, contributing to the growth of around **30 companies**, and will continue supporting this and additional initiatives throughout 2026.

Health Equity and Access to Medicines continued

Patient Centricity

We put patients at the center of everything we do and uphold the principle that all individuals, regardless of background or circumstance, should have the opportunity to participate in and benefit from medical innovation.

Our approach to research and development (R&D) is anchored in the principle of patient-centricity, which ensures our innovations address real-world health challenges, such as health equity and access to medicines, to delivering better health outcomes through our Pivot to Growth strategy.

In 2025, Teva created the Patient Engagement Framework to ensure that patients' perspectives are integrated across the entire life cycle of drug development – from early discovery through to post-approval. Through a deeper understanding and insights of lived experience, Teva can make informed decisions in the R&D process and improve products for the patient, with appropriate guiding principles and processes.

The Teva Patient Impact Roadmap is a structured framework that defines clear R&D stage gates and objectives:

- understanding disease prevalence, scope and unmet needs;
- mapping the patient journey;
- incorporating patient input into product design, clinical study development, access planning and regulatory strategies; and
- ensuring transparent communication of trial results and outcomes.

The Patient Engagement Framework executes Teva's Patient Impact Roadmap, according to the R&D Patient Engagement policy, which ensures fair and ethical patient engagement interactions and protects patients' rights and privacy. We embed patient insights into research, development and access strategies to advance outcomes that matter most to patients. The Roadmap also provides internal governance and accountability mechanisms, guiding cross-functional teams in how to collaborate effectively with patients and patient organizations.



Teva employees at our Harlow site, UK

Health Equity and Access to Medicines continued

Driving Patient Centricity in Clinical Trials

As we are in the acceleration phase of our Pivot to Growth strategy, we are continuously innovating to improve representation, transparency and accessibility. By 2030, 100% of new innovative clinical trials will include input and insights from patients or caregivers regarding the clinical trial design or patient or caregiver journey by focusing on four main areas, as described below.

2025 Progress for Patient Centricity in Clinical Trials

Target	Area and Approach	2025 Progress
Patient and Caregiver Engagement 100% by 2030 of new innovative clinical trials will include input and insights from patients or caregivers regarding the clinical trial design or patient or caregiver journey.	We are involving patients and caregivers in designing and reviewing documents for clinical trials, leading to better data, engagement and real-world insights.	<ul style="list-style-type: none"> Developed the Patient Engagement Framework. 100% of new early innovative clinical trials received insights from patients or caregivers regarding the clinical trial design or journey. Partnered with patient advocacy organizations to create patient-facing materials for patients diagnosed with Celiac Disease and continuous partnership with a vitiligo patient organization. This allows for stronger study awareness among patient communities. 50% of new innovative clinical trials included patient-facing materials reviewed/created by a patient/patient organization.
Inclusivity 100% by 2030 of applicable new innovative clinical trials, regulatory authority dependent, will have diversity action plans created.	We aim to give equal opportunities for all interested patients by enrolling participants from diverse backgrounds. This improves our understanding of how our medicines impact a broader range of people and supports our objective of developing and producing medicines that are effective and safe for more patients.	<ul style="list-style-type: none"> Expanded awareness and capabilities: Delivered internal and external training on the importance of diversity in clinical trials. In 2025, >90% of applicable employees completed the training. Engaged under-represented communities: Executed targeted clinical-trial education programs to increase understanding and participation among populations historically excluded from research. Advanced inclusive study design: Supported recruitment planning – resulting in 50% of applicable new investigational products now having dedicated diversity plans.
Decentralized Trials 100% by 2030 of new applicable clinical trials studies will be assessed for the option or requirement for decentralized components.	We are designing trials for flexibility and accessibility, including remote visits and technology solutions to overcome site access challenges and reduce patient burden due to trial complexity.	<ul style="list-style-type: none"> Executed a strategic framework of evaluating, exploring and implementing remote components to improve flexibility. 100% of applicable clinical trials were evaluated under this framework. All new studies give the patients the opportunity to complete certain visits at home to support flexibility in joining and staying on clinical trials.
Site Partnerships 100% by 2030 of new applicable clinical trial studies will have a pre-study site engagement activity.	We are collaborating with trial sites and coordinators to improve trial execution, remove recruitment barriers and support remote processes.	<ul style="list-style-type: none"> Partnered with clinical trial sites for future support on gathering insights on how we design clinical trials and preferences/recommendations for successful execution (such as strong sponsor site partnership, eliminating barriers related to recruitment or retention and optimizing remote visits). Pre-study site activities focus on design protocol and complexity.

Health Equity and Access to Medicines continued

Advancing Cutting-edge Science and Innovation

We believe that innovation must serve the needs of both patients and the wider society to consider unmet global health needs and drive better health outcomes for patients.

We are maximizing the potential of emerging technologies – including AI, human-ex vivo systems (organoids), industry 4.0 smart manufacturing, digital health and biotech – to transform our business and improve global patient outcomes.

We engage on innovation with a range of stakeholders, including industry alliances, healthcare institutions and technology partners. Teva Rise is our new platform to encourage support for innovators in the pharmaceutical industry, which you can read more about [opposite](#).

Innovation Collaborations Around the World

We actively participate in several industry initiatives to enhance access to medicines and health equity; working groups convened by IFPMA, including the NCD Taskforce ahead of the 2025 UN High-Level Meeting on the Prevention of Non-communicable Diseases and Mental Health (NCDs) and the Access to Oncology Medicines (ATOM) Supporter Group, aimed at increasing access to essential cancer treatments in LMICs.

Our engagement approach with academia and startups included approximately 75 projects in 2025:

- In the USA, we have partnerships with labs in key universities to foster innovation, including Thomas Jefferson, Pittsburgh and Oklahoma. Teva's virtual course for drug discovery and development has attracted thousands of participants across universities that also visit Teva's R&D centers.
- In Europe, we have been part of the Innovative Medicines Initiative (IMI) and Innovative Health Initiative (IHI) since 2019. It is Europe's largest public-private partnership in life sciences and aims to develop next-generation vaccines, medicines and treatments.
- In 2025, we participated in more than five IMI/IHI consortia – from drug discovery to late development and regulatory aspects. One new consortia is creating sandbox tools for regulatory processes.



Teva R&D employee at our Netanya site, Israel

Health Equity and Access to Medicines continued

Our engagement approach in Israel restarted in 2020 and, since then, we have established approximately 75 projects with Israeli researchers. We focus on searching and mapping innovation and collaboration activities, leveraging the country's technology and science ecosystem, given Teva's deep ties and historic innovative successes, including academic collaborations. We have received over 20 partnership grants to date from the Israel Innovation Authority.

In 2025, we continued to support key initiatives in our Israel-based collaborations:

- **AION Labs:** An alliance between Teva and three other global pharmaceutical companies, Amazon and two VC funds: the Israel Biotech Fund and Amity. AION is a venture studio creating and supporting start-ups focusing on artificial intelligence (AI) in drug discovery and development. We play an active role in AION Labs by providing training and engagement. AION has created eight new start-up partnerships. In 2025, we supported three of the AION portfolio companies: CombinAble, DeNovAI and Cellyrix.
- **Organospheres:** We work with multiple start-ups, pharma companies and academic groups through Organospheres, a global consortium that is developing various human ex-vivo 3D systems, which could potentially provide an alternative to animals being used in preclinical studies, this is in accordance with new FDA recommendations of reducing use of animals.

- **The BioInnovators Forum:** Each year we offer 30 specialist PhD and post-doctorate students mentorship and training on translational research, and an annual innovation competition for students to develop solutions to unmet medical needs. The program has attracted over 200 graduates since inception, leveraging the skills of young scientists to drive future medical innovation. In 2025, entries included an at-home urine-based detection kit for flares in inflammatory bowel disease (IBD), using synthetic bacteria sensors, and a multi-layer patch for early detection and monitoring of ITP and platelet reduction. This program has also been a source for identifying scientific talent to bolster our R&D function.

Since 2020:

75
projects with Israeli researchers

20
partnership grants received from Israel Innovation Authority

200
students taken part in BioInnovators Forum

Case study

Teva Rise

Accelerating Patient Impact and Business Transformation by Harnessing Disruptive Technologies



The pharmaceutical industry is undergoing a revolution powered by innovative technologies. AI and digital transformation are reshaping and accelerating drug development, manufacturing and patient care. To meet this shifting landscape, in 2025 we launched Teva Rise – an open call to innovators around the world.

Rise connects start-ups and technology innovators working on disruptive technologies, such as AI, smart manufacturing, digital health and biotech, with our business units to co-create innovative healthcare solutions. This powerful example of our Pivot to Growth strategy in action aims to connect with the world's most brilliant minds and give them access to our global ecosystem to co-create solutions.

Revolutionizing Patient Care by Transforming our Business

In its first year, Rise targeted seven challenges across R&D, commercial and manufacturing and supply chain, each aligned with one of Teva's strategic goals and sponsored by a senior Teva business leader. Challenges reflect real-world Teva business priorities – for example, looking at how we might use human-based systems to test innovative biologics, or how we can use risk assessment tools. 2026 will see a second wave of Rise challenges being launched.

Offering Innovators a Global Platform

The most compelling ideas progress to a pilot phase for validation: testing, scaling and measuring their solutions across Teva's global ecosystem. By pinpointing the highest potential concepts, the program is fueling exciting collaborations and driving real innovation and progress.

Health Equity and Access to Medicines continued

Public Health Research

Improving public health is fundamental to who we are and what we do. As a biopharmaceutical company, advancing health impact is inseparable from how we discover, develop and deliver medicines. Our strong capabilities in health economics and public health research ensure every innovation is evaluated not only for clinical efficacy, but for its real-world value to patients, health systems and society. Through rigorous investigation and transparent publication, our work helps shape evidence-based care, inform policy and expand access, translating scientific breakthroughs into measurable improvements in people’s lives and community health.

Through Teva’s broad portfolio and robust pipeline of medicines, we are driving meaningful impact on improved health outcomes and addressing unmet patient needs, helping to deliver better care for communities around the world.

In 2025, Teva’s R&D teams were involved in 162 congress presentations and published 72 peer-reviewed articles on drug development studies to improve research technologies and to evaluate the efficacy and safety of Teva’s medicines for patients suffering from psychiatric and neurologic disorders, migraine and immunologic diseases.

Highlights include:

- Teva’s R&D bench scientists contributed to industry consortium presentations on new methodologies and technologies to reduce the use of animals in drug research, pharmacokinetic modeling to predict drug exposure to infants during breastfeeding and the utilization of decentralized trial methods.
- Teva’s medical and clinical development teams worked together with esteemed clinicians on studies for patient-centric topics in psychiatry and neurological conditions, such as the multidimensional impact of tardive dyskinesia, a disease that remains under-diagnosed and under-treated.


162

research presentations by Teva

72

peer-reviewed articles across scientific and medical journals published

Teva Research and Development Academic Papers Published on PubMed in 2025 (72 total)



Patient Safety and Quality

Patient safety and quality is foundational to everything we do. It is our responsibility to promote health and ensure that patients and healthcare professionals can trust our medicines.

Patient Safety

We embed patient safeguards across the entire product life cycle to protect patient health. Our Global Patient Safety and Pharmacovigilance (GPV) unit continuously evaluates product benefit and risk profiles and implements measures to minimize risk.

30

Teva subsidiaries and 82 third-party sites audited

100%

of medicinal products (Teva portfolio and clinical trial pipeline) are regularly assessed for patient safety

Governance

Our Global Head of Patient Safety leads Patient Safety at Teva, reporting directly to the Executive Vice President, Global Head of R&D. He chairs the Corporate Safety Board (CSB), which reviews and assesses Teva's product portfolio from a Patient Safety perspective, including products in development.

Teva's product-specific patient safety groups (PSGs) support the CSB. They continuously monitor and evaluate outputs from global data collection systems, including product usage data, results from Teva studies and all relevant scientific publications for all Teva medicinal products.

Guiding Document

→ [Teva's Position on Patient Safety](#)



Zion, living with Huntington's disease

Patient Safety and Quality continued

Prioritizing Pharmacovigilance

Our global pharmacovigilance (GPV) system ensures our medicines meet our high safety standards. This GPV system includes procedures for adverse events case management, signal detection, risk minimization, aggregate reporting and interactions with health authorities, as well as audits, deviation management, monitoring activities and training. It harnesses both technology-led insights and the in-depth knowledge of expert physicians, pharmacists and other healthcare professionals. This approach enables us to swiftly identify, investigate and mitigate all safety signals around new or known adverse events. Regular supervision by the Food and Drug Administration (FDA), the European Medicines Agency (EMA) and other health authorities, along with inspections, confirms that we are complying with all legal requirements.

Ensuring Product Safety

In 2025, we:

- Enhanced our patient safety database with new features, ensuring consistency and improving quality.
- Reviewed more than 40,000 drug-event combinations and more than 140,000 literature abstracts to determine new potential risks. Over 1,400 aggregate safety reports recorded the results, which were shared with health authorities as per local requirements.
- As a result, we initiated safety label updates for more than 300 compounds, including newly detected risks and precautionary measures.
- Provided 371 additional measures, including non promotional educational materials for patients and HCPs on how to use a given product safely, to manage, avoid and minimize health risks and improve treatment outcomes.
- Started Adverse Events reporting apps in Russia and Kazakhstan to streamline safety data collection.

Our GPV Audit Program regularly audits Teva’s subsidiaries and partners. In 2025, we audited 30 subsidiaries and 82 third-party PV systems. Although we identified no critical observations, we will always undertake corrective and preventative actions on all observations.

We also contribute to systematic patient safety improvements via industry associations, including Medicines for Europe (MfE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). These associations enable us to improve data collection, signal detection and risk minimization, thereby maximizing treatment benefits for patients.

Safety Training and Awareness

All employees must complete patient safety training upon joining Teva and annually thereafter. The training covers PV, communication and reporting protocols to prepare our employees for rapid collection and sharing of safety information. In 2025, over 99% of assigned employees worldwide completed our annual PV refresher training.



Teva employee in Japan

initiated
>300

label updates and

>370

additional measures introduced to minimize patient health risk

Patient Safety and Quality continued

Innovation in Patient Safety Highlights

In 2025, we:

- Launched a Teva AI-based literature summarization tool to help with literature reviews for early safety signal detection.
- Implemented a new global regulatory intelligence tool to promptly track new worldwide regulatory requirements.
- Introduced a new signal detection tool to find early potential safety issues with medicines by analyzing Teva data and reducing false positive signals, so experts can make informed decisions faster to protect patient safety.

Teva is exploring initiatives with national authorities and industry associations across the EU, to increase the use of digital tools and reduce the use of paper educational materials and their associated environmental impact. We have already implemented digital tools in Greece within the HCP prescribing system, with Teva being at the forefront of this initiative.

We believe that AI can provide great potential in the realm of improved patient safety. We are increasing the use of AI tools in PV to improve operational efficiency, compliance, quality, risk management and patient safety. We have also implemented our digital platform for risk communication (aRMM) to enhance communication with patients and HCPs about newly identified risks using new technologies.

Patient Safety Awareness – Putting Patients First

In 2025, Poland, Spain, Chile, Greece, Israel and Ukraine introduced PV awareness and educational campaigns for HCPs, emphasizing the critical role of PV in minimizing risks associated with product use.

Aligned with the WHO World Patient Safety Day theme, we ran a social media campaign about pregnancy prevention programs, with information about how Teva PV works to advance maternal and fetal health through proactive safety measures.



We believe that AI can provide great potential in the realm of improved patient safety. We are increasing the use of AI tools to improve patient safety.

Teva lab employees in Chile

Patient Safety and Quality continued

Counterfeit Medicines

At least one in ten medicines in LMICs is counterfeit, meaning these countries are spending \$30.5 billion a year on medications that may contain no active pharmaceutical ingredients (APIs) or have an incorrect concentration of API and/or may include contaminants. This situation could lead to patients not receiving the appropriate treatment or having their lives put at risk.¹

We work with governments, our industry peers and enforcement authorities to prevent and control counterfeit medicines (those manufactured without the strict standards and controls of authorized manufacturers).

Especially at risk are vulnerable populations in countries with no social protection, weak health systems, poor regulation, disrupted supply chains and limited access and affordability.

Our Global Corporate Security unit manages our supply chain security.

60,331

websites, marketplaces, advertisements and social media posts for counterfeit medicines were reviewed in 2025

86%

enforcement rate

Governance

Our Global Anti-Counterfeiting Oversight Committee reviews anti-counterfeit controls, counterfeit-related risks and mitigation plans. The Committee includes representatives from across Teva, working closely with our Global Quality Operations team to prepare for and manage any counterfeiting threats.

Global Trade Investigations and Inspections

We investigate global trade in substantial volumes of medicines, focusing on import and export customs data. In 2025, we identified entities involved in illicit manufacturing, trade and the distribution of falsified medicines and illegal diversion of authentic medications. We conducted market inspections in African and Middle Eastern markets and investigations in Turkey, China and the US. Information from our investigations, monitoring and inspections led to raids, seizures and arrests.

Online Monitoring and Intellectual Property (IP) Enforcement

By monitoring 20 key products online, we detected and reviewed 60,331 websites, marketplace advertisements and social media posts in 2025: 1,608 were deemed high risk and sent for IP enforcement, and removed, achieving an 86% enforcement rate.

Public Awareness and Enforcement Authorities Training Program

Through our social media information campaign in Chile, we are raising awareness of the risks of buying medicines through unauthorized channels and the dangers of counterfeit products. Our 2025 campaign included 13 awareness videos, which generated over 4.4 million views.

Teva believes in public-private partnerships tackling the impact of illicit medicines. In 2024, we launched a training program for authorities to identify unlawful Teva medicines and act against them. In 2025, our program delivered eight sessions in-person and online to 682 officers in six countries. Attending authorities included customs, IP regulators, health and medicine agencies, and police representatives.

Public Health Programs

We participate in various public health access programs aimed at preventing the illegal purchase and use of counterfeit medicines, such as Breast Care International in Ghana and Global HOPE in sub-Saharan Africa. For more details, see [page 20](#).

Supply Chain Security and Legal and Regulatory actions

We collaborate with worldwide health, drug, law enforcement and customs authorities, including US FDA, UK MHRA, the Market Supervision Authority in China (local), Europol and Interpol, ISP Chile, Dubai DED, Sharjah DED, Carabinieri and AIFA.

Our membership of global organizations supports the fight against counterfeit medicines and enhances public health through training, standards monitoring and enforcement. Our memberships include:

- Pharmaceutical Security Institute (PSI): focuses on protecting public health, raising awareness about counterfeit medicines and initiating enforcement action through authorities. We participate in PSI's cross-industry Disruption Special Projects to prevent the illicit online sale of counterfeit, substandard and unsafe medicines, and to remove illicit sales.
- React: supports members with customs protection, market monitoring and online enforcement to combat trading in counterfeit products.
- Transported Asset Protection Association (TAPA): provides intelligence, industry standards, training, networking and representation solutions for in-house security programs.

1 1 in 10 medical products in developing countries is substandard or falsified. Source: World Health Organization, <https://www.who.int/news-room/fact-sheets/detail/substandard-and-falsified-medical-products>

Patient Safety and Quality continued

Quality Medicines

Millions of patients rely on our products every day, so we are committed to providing them with safe, effective, high-quality medicines that reflect our purpose: we are all in for better health.

Quality is a primary focus at all 46 of our manufacturing facilities and for every Teva employee, and our quality commitment extends across our supply chain. We are dedicated to maintaining the highest manufacturing standards, processes and procedures to ensure our products always meet or exceed customer and regulatory quality expectations.

~3,700

quality professionals at Teva bringing medicines to market

82

routine inspections resulting in no critical outcomes or observations



Our Quality Management System

We deliver high-quality medicines and have a robust Quality Management System (QMS). We perform quality testing using diverse analytical tools, equipment and methods throughout the product life cycle – from development to the pharmacy shelf. Everyone at Teva is responsible for ensuring we continue to meet all quality requirements defined by our QMS and conduct activities with the highest level of quality.

In 2025, we updated our quality-related policies and standard operating procedures, based on internal and external quality intelligence, to ensure best practice behaviors and regulatory compliance.

In addition to our own strict standards, the 66 billion tablets and capsules we manufacture annually must meet the relevant regulatory requirements of the 57 markets where we supply our products. The processes involved in meeting these requirements ensure that we proactively identify and tackle any quality issues. Throughout 2025, we continued to manage regulatory agencies' inspections, with 82 routine inspections, resulting in no critical outcomes or observations.

Governance

Our Board-level Compliance Committee receives updates of quality compliance KPIs, regulatory inspections and complaints.

Quality compliance is managed by our Senior Vice President, Global Quality and Chief Quality Officer, who reports to the Executive Vice President, Global Operations. They ensure the design, implementation and continuous improvement of our Quality Management System.

Teva's Global Quality Leadership team facilitates the development and implementation of our Global Quality strategy.

Guiding Document

→ [Teva's Position on Quality Medicines](#)



Teva employee in Germany visually inspecting nasal spray

Inclusion and Diversity

Our approach to inclusion and diversity shapes the way we work, how we treat each other and how we show up for patients.

Our commitment to inclusion and diversity (I&D) is based on merit, and woven into various aspects of our business; from how we develop our people and strengthen leadership, to how we work and communicate with external stakeholders. We believe that a diverse team drives innovation and creates a positive impact for patients and communities worldwide. It not only strengthens individual growth – it also strengthens our organization.

Beyond our own culture, we are determined to advance health and enhance business resilience by designing inclusive clinical trials, partnering with diverse suppliers and ensuring our communications are culturally relevant and representative of the patients we serve.

In 2025, we continued to evolve our I&D approach and are developing roadmaps and frameworks.

Our evolving I&D people approach aims to seamlessly embed I&D into all relevant people touchpoints and will focus on three areas that align with our business objectives: Psychological safety, Neuro-inclusion and Excellence across ages.

- Psychological safety ensures we offer a safe space for our people, and a speak-up culture to meet our high ethical standards.
- Neuro-inclusion represents a high awareness and sensitivity toward neurodiversity, complementing therapeutic areas consistent with our medicine portfolio and pipeline.
- Excellence across ages appreciates the representation and contributions of different generations in our workforce, as well as the broader demographic shift toward an aging global population.

Teva's I&D Pillars

Our evolving I&D approach integrates inclusion into all people touchpoints, with a focus on psychological safety, neuro-inclusion and supporting excellence across all ages.



Governance

Fostering Inclusion and Diversity (I&D) is a team effort, led by a dedicated Global I&D Lead, who is responsible for our global I&D people approach, initiatives and partnerships, working directly with our Executive Vice President, Chief Human Resources Officer.

Our I&D Steering Committee, co-chaired by our Global Head of Sustainability and our Executive Vice President, Chief Human Resources Officer, is responsible for shaping and steering all I&D activities and updates our Sustainability Steering Committee.

Guiding Document

[Teva's Position on Inclusion and Diversity](#)

Recognition

In 2025, Teva was recognized in the Disability:IN's Annual Index as a "Best Place to Work for Disability Inclusion", which reflects our ongoing commitment to advancing disability inclusion and accessibility in our workplace. We also received an "excellent" score of 100 in the Human Rights Campaign Foundation's 2025 Corporate Equality Index, which designates Teva as a leader in workplace equality.

Inclusion and Diversity continued

Inclusion and Diversity Culture

Based on strong foundations, our data shows we are making continued progress toward a truly inclusive work environment at Teva. In 2025, our annual Organizational Health Survey (OHS) showed 90% of Teva employees felt they were treated with respect (vs. 88% in 2024), and 83% (vs. 81% in 2024) felt Teva had an inclusive culture.

Inclusive Leadership Development

We recognize the importance of inclusive leadership and ensure consistent training quality and accessibility for all managers across Teva.

Our leadership programs provide equal access to all employees of our management teams, including First Line Leaders, Senior Leaders and Executive Leaders. In 2025, participation by women in the programs increased to 53% across all seniority levels.

In 2025, 50% of all Teva management level roles were held by women, as were 35% of our roles at Vice President level and above (vs. 34% in 2024).

Inclusive Talent Acquisition

We hire on merit, regardless of background. Our talent acquisition process is inclusive and ensures equal opportunity to reflect the diversity of the patients and communities we serve. Our recruiting managers and recruiters have I&D supporting tools that align with our evolving business needs to drive organizational growth.

Promoting Inclusion at Teva

To develop our positive culture, inclusion and employee experience at Teva, we support Employee Resource Groups (ERGs) in various countries and regions, which are open to all employees and bring together colleagues to network, support belonging, develop skills, mentorship and leadership opportunities. ERGs align their activities with business objectives, leveraging the unique perspectives, experiences and skills of their members to drive innovation, enhance employee engagement and support organizational goals.

Teva STARS is our special recognition program linked to our corporate values. It is accessible to all colleagues and helps to create a culture of inclusion and respect, where any employee can recognize another colleague with a token reward.

Ensuring Pay Equity

We aim for pay equity at all levels.

Our culture of respect is also reflected in how we recognize and reward our people. We compensate our employees fairly based on merit, market norms and in line with legal requirements for wages and social benefits, often exceeding legal minimum levels.


In 2025, we continued to assess pay differences across our employee population, using our global methodology, which includes pay differences between men and women and across other disparities among employees of the same function, level and location. Findings revealed that we have a near-zero gender pay gap (-0.7%) among our employees at the same level, function, profession and location, and that we pay women roughly equally to men for base salaries.

There are no barriers to success based on gender at Teva. We always take action to minimize any gaps identified during our annual rewards cycle. Because pay differences are often created when employees are hired or promoted, we are continuing to work with our talent acquisition team to introduce new tools and approaches to avoid pay differences during the job offer stage.


Our 2025 data for gender breakdown shows that women and men are equally represented on an overall basis, with 48% of roles being held by women.

Employees by Gender


Total Employees



Total Management Positions



Executives/Senior Managers



● Women ● Men

Inclusion and Diversity continued

Inclusion and Diversity Across the Globe

Progress in 2025



Brazil

Activities during Black Awareness Week, and more general educational sessions and conversation circles on gender equity, race and ethnicity, LGBTQIAPN+ community and generational diversity.



Germany

TeamEVA is a site-based initiative dedicated to empowering women at Teva and providing a platform for exchange and development. Additionally, through the FemForward initiative, we connect women beyond the company across the Danube Valley region to foster networking and empowerment.



Latin America (LATAM)

Created the Inclusive Language Guide, including recommendations to promote respectful and equitable work environments. Also carried out regional training for the LATAM Human Resources team on neurodivergence to apply across end-to-end employee processes.



Chile

Produced Maternity Guide, including benefits, partnerships and recommendations for mothers, and introduced lactation rooms at our production site and offices.



Hungary

Local teams participated in global initiatives such as Pride Month, Diversity Month and Women’s Day campaigns, which supported ERG goals by raising awareness and fostering inclusion. These activities also strengthened employee engagement and laid the foundation for introducing local ERGs in the future.



Mexico

Introduced a new Inclusion Mailbox to confidentially share experiences and testimonials, and ran a talk for employees on “The Impact of Diversity at Work,” including a TED-style talk and reflection space.



Finland

Ran an improvisation theater session on how to work and communicate with different personalities in various work-life situations.



UK

Launched neurodiversity training to all employees, including a special module aimed at managers, completed in Teva’s online training platform.



R&D lab technicians in Westchester, New York, USA

Employee Health, Safety and Well-being

Our employees are at the heart of what we do. We are committed to protecting and enhancing their physical and psychological health, and overall well-being, which supports sustainable business growth.

Our Environmental, Health and Safety and Sustainability (EHS&S) Management System (EHSMS) establishes the policies, standards and procedures that define how we manage risks, protect health and safety at work and meet our regulatory and corporate EHS&S obligations.

Progress on Targets

● Achieved ● In progress ● New target

2025 Targets	Progress	Status
Achieve a total recordable incident rate (TRIR) of <0.23 ¹	0.22	●
Achieve a process safety event (PSE) rate of 0.01	0.003	●
Maintain an on-time corrective and preventative actions (CAPA) closure (OTCC) of 95% or above	97%	●
Maintain a 90% or above regulatory inspection with no further action required	92%	●
Maintain a closure rate of above 80% for all EHS&S observations	91%	●
New target: Reduction of significant risk by 10% by 2026 vs. 2025 baseline	-	●
New target: Achieve a Safety Leadership Index of 95% by 2026	-	●
New target: Achieve 0 overdue CAPAs by 2026	-	●

1 TRIR includes Teva and contingent employees, injuries and illness and is calculated based on 200,000 hours.

Governance

Our Global Environmental, Health, Safety and Sustainability (EHS&S) Committee ensures appropriate engagement and oversight of material issues. Health, safety and well-being management are the operational responsibilities of each business unit's line management. Managers are supported by our Global EHS&S function, which reports to the Senior Vice President, Global Quality and Environment, Health, Safety and Sustainability (EHS&S), who reports to the Executive Vice President, Global Operations.

All Teva sites are part of the EHS&S governance model, with site EHS&S in most instances being part of the site leadership team reporting directly to the site General Manager, while also having a parallel dotted reporting line to Global EHS&S. Each site is required to hold a periodic management review and, where required by local regulation, also an EHS council with employee representation.

In general, well-being and benefits are managed at a local level.

Guiding Document

➔ [Teva's Position on Occupational Health and Safety](#)



Teva warehouse employees in Mexico

Employee Health, Safety and Well-being continued

Maximizing Employee Health and Safety

In 2025, our approach to Health and Safety (H&S) encompassed the focus areas of risk and culture – supported by two key enablers – IT systems and the simplification of our Environmental, Health and Safety Management System (EHSMS).

Our focus on risk in 2025 centered on reducing material EHS&S risk. We are standardizing and evolving site risk registers to reinforce accountability, strengthen risk-informed decision-making and support a safer, more resilient organization.

Initiatives to develop our EHS&S culture at Teva during 2025 included a pilot of “Intentional Leadership”, a method to engage, motivate, track and improve EHS&S performance, through a system of coaching to predefined behaviors at all levels. In addition, we rolled-out our annual EHS&S Week and EHS&S Excellence Awards across the organization.

In line with best-in-class EHS&S practice, during 2025, we introduced an updated program at Teva sites to identify and report events that had the potential to cause serious injury or fatality (SIFp). This helps us learn from “precursor” events – situations that could have led to severe outcomes but did not – and take proactive steps to prevent similar incidents in the future.

In 2025, we started a phased multi-year simplification of our EHSMS to ensure we are providing clear, unambiguous expectations to our sites and colleagues.

Throughout 2025, colleagues continued to engage with their local EHS&S observation reporting systems. The process provides a strong link between day-to-day work and organizational learning, offering an accessible and effective mechanism to report and address hazards, risks, ideas and recommendations. We encourage colleagues to submit observations and, in 2025, employees exceeded our internal targets, raising over 66,000 observations with a 91% closure rate (against a target of above 80%).

In 2025, we continued to improve our key health and safety metrics. We saw:

- 80% improvement in Process Safety Event (PSE) Rate vs. 2024; and
- 6% improvement in Total Recordable Incident Rate (TRIR) for Teva employees and contingent workers.


80%

improvement in Process Safety Event (PSE) Rate vs. 2024

6%


improvement in Total Recordable Incident Rate (TRIR) for Teva employees and contingent workers vs. 2024

Total Recordable Incident Rate (TRIR): Teva Employees and Contingent Workers



The figures shown in the graph above are calculated on 1,000,000 hours worked.

Process Safety Event (PSE) Rate



The figures shown in the graph above are calculated on 200,000 hours worked.

Contributing to Employee Well-being

Employee well-being is vital to our success – fueling performance, enhancing morale and engagement, and contributing to innovation and growth. It is multifaceted, shaped by physical, emotional, social and financial factors.

Our global policies and local initiatives help to reduce stress and promote a healthy work-life balance for our employees.

In September 2025, we celebrated Well-being Month, with a focus on Preventative Health. We hosted a global webinar for employees on Taking Charge of Your Long-Term Health, with activities and educational events to support them. We have identified four focus areas: know your numbers, schedule screenings, reduce risk through lifestyle changes and make small choices for big impact.



Teva well-being event, employees in China

Healthy People: Additional Highlights

Developing Talent

We provide a range of learning and development programs for employees to support their professional growth and help them achieve their full potential.

Our Shape Your Career program is the foundation for career growth at Teva. In 2025, we integrated career management skills into our framework to form the foundation of this program, with development opportunities such as learning sessions for employees and managers, and a self-assessment tool called Career Pulse.

Our online learning Global Skills Enhancement program, TevaGrow, helps Teva employees develop essential cross-functional skills.

In addition, employees viewed 50,894 online courses in the LinkedIn Learning platform and gained over 3,561 new skills in 2025.

3,561

new skills gained by employees

50,894

online training courses viewed by employees



Teva employees in India

Healthy Planet

In this Section

Managing our Environmental Impact	40
Climate Action and Resilience	42
Pharmaceuticals in the Environment	48
Product Sustainability	51
Healthy Planet: Additional Highlights	52

100%

renewable electricity via *three* long-term *power purchase agreements* to date, to cover various Teva sites in Europe and Israel¹

73%

of our applicable sites have achieved *safe discharge* levels of *antimicrobials*

5 products

assessed to date for their *life cycle environmental* or *carbon footprint* impacts

“I am proud to keep our critical systems running safely and efficiently, knowing that each improvement helps reduce waste and emissions and protects the people and planet we all depend on.”

Paul Bloching
Critical Systems Mechanic

[Read more on page 40](#)



Paul taking a wastewater sample to be sent for analysis from Teva's Ulm site's wastewater treatment plant ultrafiltration unit, Germany

¹ In some locations, offices and/or facilities with negligible energy consumption may be excluded.

Managing our Environmental Impact

At Teva, we are all in for better health. To deliver on our vision of a healthy future, we must ensure a healthy planet. A healthy environment could prevent nearly a quarter of the global disease burden.¹

We recognize that we need planetary health to sustain humanity's health, and are committed to reducing our environmental impact and supporting business growth and resilience.

Our environmental initiatives focus on addressing climate change and pharmaceuticals in the environment (PiE), as well as enhancing the sustainability of our products across their life cycle and reducing our impact in areas such as waste and water. We have clear goals to address environmental challenges.

Our Environmental, Health and Safety Management System (EHSMS) provides a structured framework to advance environmental sustainability and regulatory compliance through rigorous standards. Our EHSMS is applicable to all of our sites.

In 2025, in addition to periodic updates to some of our Environmental standards, aimed at aligning our actions with our environmental sustainability objectives, managing risks and compliance expectations, we also continued to implement our dedicated Teva office standard to reach more employees and implement EHS best practices across the organization.

Governance

Our Board-level Compliance Committee and Sustainability Steering Committee oversee the performance of our Healthy Future strategy, including healthy planet focus areas, through periodic updates.


Our Global Environmental, Health, Safety and Sustainability (EHS&S) Committee supports management oversight and engagement on material EHS&S topics, including environmental sustainability, occupational health and safety, and emerging risks.

The Vice President, Global EHS&S is responsible for the strategic leadership, governance and oversight of Teva's global EHS&S framework, including environmental management and sustainability programs, and for monitoring performance against corporate objectives and regulatory requirements. The Global EHS&S function reports to the Senior Vice President, Global Quality and EHS&S, who in turn reports to the Executive Vice President, Global Operations. Local site management is accountable for EHS&S compliance and performance.

A multidisciplinary Global Environmental Sustainability Taskforce supports execution of Teva's environmental sustainability strategy by advancing process against targets and helping to define, coordinate and monitor plans for priority environmental topics.

Guiding Document

- [Teva's Position on Environmental Sustainability](#)
- [Teva's Position on Pharmaceuticals in the Environment](#)



Teva's virtual power purchase agreement (VPPA) project in Bulgaria

¹ Environmental health. Source:World Health Organization:https://www.who.int/health-topics/environmental-health#tab=tab_1

Managing our Environmental Impact continued

Progress on Targets

● Achieved
 ● In progress
 ● New target

Subtopic	Targets	Progress	Status
Climate Action and Resilience			
Decarbonization	Achieve net zero emissions ¹ across our operations and value chain by 2045	See Scope 1, 2 and 3 progress below	●
	Reduce absolute Scope 1 and 2 greenhouse gas (GHG) emissions by 25% ² by 2025 and 46% by 2030 (vs. 2019) ³	Reduced by 39%, achieving 2025 target	●
	Reduce absolute Scope 3 GHG emissions by 25% by 2030 (vs. 2020) ³	Reduced by 32%	●
	Engage with significant suppliers to achieve 80% committed or approved by the Science Based Targets initiative (SBTi) by 2030	52% of suppliers with committed or approved SBTi targets	●
Renewable Electricity	Achieve 100% renewable electricity use by 2035	60% use of renewable electricity	●

Pharmaceuticals in the Environment

Antimicrobial⁴ Resistance	Achieve safe discharge levels ⁵ (RQ <1) ⁶ for antimicrobials for 80% of applicable Teva sites by 2030 and 100% by 2035	73% of sites with RQ<1	●
	Assess discharge levels of 100% of antimicrobial supplier sites by 2030: <ul style="list-style-type: none"> At least 50% of antimicrobials supplier sites to have safe discharge levels⁵ (RQ <1)⁶ 50% of remaining supplier sites with discharge levels above safe limits to have set up mitigation plans 	58% of suppliers answered our AMR survey	●
Priority Active Pharmaceutical Ingredients (APIs)⁷	Achieve safe discharge levels (RQ <1) ⁶ for priority APIs ⁷ for 50% of applicable Teva sites by 2030 and 100% by 2040	42% of sites ⁸ with RQ<1	●
	Assess discharge levels of 100% of priority API ⁶ supplier sites by 2030: <ul style="list-style-type: none"> At least 50% of priority API supplier sites to have safe discharge levels (RQ <1)⁶ 50% of remaining priority API supplier sites with discharge levels above safe limits to have set up mitigation plans 	Strategy in development	●

Subtopic	Targets	Progress	Status
Appropriate Use of Antibiotics	Reach 40,000 targeted healthcare professionals and 400,000 patients with educational materials about appropriate antibiotic use to contribute to AMR stewardship efforts by 2026	65,537 HCPs and 398,250 patients reached ⁹ by our AMR stewardship campaigns in Germany and Kenya	●
Life Cycle Assessment	Assess the environmental life cycle impact of key products by 2030 ¹⁰	5 products assessed	●

Product Sustainability

See Teva's [Healthy Future Report](#) Disclosures for complete details of environmental data, including historic data restatements.

1 According to the Science Based Targets initiative (SBTi) net zero standard. We intend to make an official SBTi net zero commitment in 2027.

2 Sustainability-linked bond target (2030 target has been validated by SBTi as meeting their near-term standard).

3 Validated by SBTi.

4 To enhance alignment with the actual scope of the KPIs, the term 'antimicrobials' was introduced this year, and the prior terminology was revised.

5 Safe discharge levels as described in the AMR Industry Alliance Antibiotic Manufacturing Standard.

6 RQ refers to the risk quotient measure of risk that compares the predicted environmental concentration to the predicted no-effect concentration (RQ = PEC/PNEC).

7 Defined by Teva as including hormones, cytotoxins and other APIs on the European Union Water Framework Watch List.

8 In 2025, the number of sites in scope for the KPI increased from 10 to 19, and now includes lower-volume sites.

9 Via digital messaging to pharmacists at the point of care. Not necessarily unique patients reached.


10 This commitment covers both Life Cycle Assessments (LCAs) and Product Carbon Footprint (PCF) assessments.

Climate Action and Resilience

We are committed to strengthening our business resilience by addressing both the causes and impacts of climate change, prioritizing energy efficiency, expanding renewable electricity use, deepening supplier engagement and advancing product sustainability.

Our 2030 near-term Scope 1, 2 and 3 GHG emission targets, validated by the Science Based Targets initiative (SBTi), are supplemented by our commitment to achieve net zero GHG emissions across our operations and value chain by 2045, supported by a transition plan.

In 2025, the Carbon Disclosure Project (CDP) again recognized our efforts and transparency on climate change, **awarding us an A-**, the score we have successfully maintained since 2022.



● Scope 1 & 2

Lever for Decarbonizing our Direct Operation

- Sourcing renewable electricity
- Energy efficiency and heat recovery
- Promote decarbonization technology

● Scope 3

Lever for Decarbonizing our Upstream Value Chain

- Supplier engagement
- Sustainable material procurement
- Eco-design integration into products

Lever for Decarbonizing our Downstream Value Chain

- Circular and resource optimization
- Transportation optimization and low-carbon vehicles

Climate Action and Resilience continued

Climate Action in our Operations

Our 2045 Net Zero Transition Plan aligns with 1.5°C and well-below 2°C pathways for Greenhouse Gas (GHG) emission reductions. The plan includes the key decarbonization levers to achieve our long-term commitments (see diagram on page 42).

Our 2030 Scope 1 & 2 comprehensive Decarbonization Plan sets out the steps required to reduce emissions in the near-term, through energy and process efficiency, renewable electricity and sourcing optimization. This plan, in part, has helped us surpass our interim 25% by 2025 Scope 1 and 2 GHG emissions reduction (vs. 2019) target, realizing a 39% reduction. During 2025, we achieved significant reductions in GHG emissions and supported our long-term operational cost efficiencies.

Energy Efficiency

Guided by our dedicated Sustainability Taskforce – a global, cross-functional team comprising Engineering, EHS&S and Global Facility Management – we have continued to implement energy efficiency and decarbonization projects across Teva in 2025.

We map energy consumption at each site to improve energy performance and systematically identify significant energy users and areas or equipment. Our sites implement local decarbonization initiatives to support progress toward our global decarbonization commitments.

In 2024–2025, the Global Environmental Sustainability Taskforce executed 136 projects, which yielded \$3.6 million in savings through energy consumption reductions in 2025.


Teva has a dedicated global fund for energy efficiency initiatives. Teva operational sites submit their proposals and, the most attractive of those in terms of expected emissions reduction, are awarded the required budget. In 2025, together with other local initiatives, this contributed to emissions reduction of 5,300 tCO₂e. We have set a 2026 fund of \$6 million, which is expected to contribute to additional emissions reduction in 2026–2028.

ESCO Projects


In addition to our in-house expertise and efforts, we also work with Energy Service Companies (ESCOs) to maximize reduction in energy use and improve energy efficiency.

An ESCO business provides comprehensive energy solutions, including audits, project design, implementation, financing and ongoing maintenance. For several years, we have leveraged the support of ESCOs to help us identify and implement energy projects, including updating production processes, ventilation and air conditioning. In 2025, we continued using this approach at selected sites.


Malta: Our collaboration with an ESCO reduced energy consumption and GHG emissions at our Bulebel site. The project included replacing steam traps and the air compressor, optimizing the chiller and implementing energy management software. The project is scheduled to complete in 2026 and deliver emission reductions of ~560 tCO₂e/yr, over 1 GWh annually in electricity savings, and diesel savings of approximately 45,000 liters a year.



Scope 1 and 2 GHG Emissions (tCO₂e)



Scope 3 GHG Emissions (tCO₂e)



Climate Action and Resilience continued

Increasing Renewable Electricity

Our target is to reach 100% renewable electricity across our operations by 2035. In 2025, 60% of our electricity was from renewable sources, up from 47% in 2024. Key initiatives that have supported our progress – and will continue to do so – include:

Bulgaria

- In 2025, we entered into a new 15-year virtual power purchase agreement (VPPA) to support the development of the Knizhovnik solar project in Bulgaria, marking Teva’s second VPPA. The project is expected to generate ~200 GWh/yr of renewable electricity and is one of the first VPPAs in Europe to integrate photovoltaic (PV) generation with battery energy storage systems. When operational in mid-2026, it will supply the equivalent of ~60 GWh/yr of renewable electricity to our operations in Europe.

Europe

- Our first VPPA, in Spain, which was entered into in 2024, started to go live in July 2025, with remaining phases to come online in mid-2026. When fully commissioned, this will supply the equivalent of ~175 GWh/yr of 100% renewable electricity to a number of Teva sites across Europe over the next ten years.

Israel

- 2025 marked the first full year for which we supplied 100% renewable electricity to all our sites in Israel, as part of a landmark long-term agreement signed in 2023.


Energy and Climate Awareness

In 2025, our Global Environmental Sustainability Taskforce conducted eight awareness and training workshops for our approximately 130-person strong Energy Champion community, each of whom manages energy consumption and leads local decarbonization efforts at their respective sites. Topics included Energy Efficiency Opportunities and Reporting, and Teva’s updated Decarbonization Model.

Capacity-building initiatives for our Energy Champions included:

- Deep-dive sessions on advanced topics such as visualizing energy flows.
- Energy Technology forums to deepen site-level energy leaders’ understanding of decarbonization technologies.
- Specialized Technology Forums to explore innovative solutions and share experiences on implementing advanced energy technologies.
- Energy Review and Energy Mapping training to equip participants with the tools to analyze and optimize energy flows in facilities.
- Heat Pump training to provide insights into heat pump technology deployment and operation, leading to improved energy efficiency.
- Refrigerant training to address best practices for managing refrigerants, minimizing environmental impact and supporting decarbonization goals.

Renewable Electricity (%)



~130

Energy Champions working to implement energy efficiency measures at our sites

60%

of our electricity is from renewable sources across all sites



Teva employee at the photovoltaic rooftop array at the Teva site in Germany

Climate Action and Resilience continued

Catalyzing Emissions Reduction in our Value Chain

GHG emissions across our value chain (Scope 3) represent around 90% of our total footprint. In 2025, we achieved Scope 3 GHG emission reductions of 32% (vs. 2020), surpassing our 2030 target of a 25% reduction ahead of time, and putting us on track for our longer-term commitments.

Most of our Scope 3 GHG emissions relate to procured goods and services required to develop and manufacture our medicines. Therefore, we engage with our significant suppliers to encourage them to reduce their GHG emissions and set targets through SBTi and provide GHG footprint data through CDP and other initiatives.

- We participate in the Energize Program to encourage renewable electricity adoption, providing education and functional support for our significant suppliers to take action on climate change. Their engagement in the Energize Program increased by 51% to 266 in 2025, from 176 in 2024.
- Out of 1,279 of Teva's significant suppliers, 664 (52%) have committed to, or already have, approved SBTi targets, of which 113 (17%) of them began the process in 2025.


- We collaborate with the CDP (Carbon Disclosure Project) and, in 2025, invited 200 suppliers to disclose their Scope 3 GHG metrics in CDP's climate questionnaire. This initiative enhances the quality of data used to calculate some of our Scope 3 GHG emissions categories. 45% of invited suppliers submitted Scope 3 metrics through CDP's questionnaire.

32%

Scope 3 GHG emission reductions vs. 2020

52%

of our suppliers have committed or obtained SBTi-approved targets



Case study

Reducing Transportation Emissions

To reduce transport-related fuel emissions, we continued implementing selected initiatives across different regions. Both our transport emissions intensity and overall transport emissions showed meaningful progress, declining by 13% and 15%, respectively, compared to 2024.

We have sustained our industry-leading ocean transport ratio of 90%, compared with air transport. We have also implemented a new ocean container process that allows sharing underutilized containers from EU origin sites to Israel and Chile. This process is reducing emissions on the selected lanes. Together with a strategic partner, we also arranged for sustainable biofuel on ocean lanes from Israel to Europe, achieving an 85% reduction in emissions on this lane.

90%

ocean vs. air ratio for site-to-market transport in 2025



Employee at the Teva logistics center in Israel in front of the van fleet

Climate Action and Resilience continued

Building Climate Resilience

We are transparent about our approach to climate risks, through our climate-related financial statement (aligned with TCFD and, for the first year, with reference to IFRS S2) on pages 62 to 70 of our [Healthy Future Report Disclosures](#).

In 2025, we enhanced our Loss Prevention Program to improve our sites' protection from climate risk, conducted physical climate risk scenario assessments and evaluated how the global transition to a low-carbon economy may affect our business under multiple climate scenarios.

Examples of how our sites are enhancing their climate resilience include:

USA

- Our site has upgraded its roof to be more resilient to powerful hurricanes. Construction work was completed in 2025, in line with Florida Building Codes, which are among the most stringent worldwide for wind and rain events. We are evaluating other Teva sites using a specialized natural-catastrophe risk assessment approach to understand potential hazard exposures and their correlation with high-value assets.

Czech Republic

- In September 2024, severe flooding across large parts of the Czech Republic and Poland posed a risk to our Opava site, which is located adjacent to a river. Owing to our robust global loss prevention program and the well-rehearsed emergency response procedures executed by the site's emergency crew, the impact was limited to minor damage. The site's flood defenses and response plans performed largely as intended, preventing potentially grave consequences. Operations were restored to near-full capacity within 60 hours, with no disruption to the supply of medicines. Following a comprehensive post-event review, the site implemented additional measures in 2025, to strengthen its flood defenses, emergency response capabilities and business continuity plans, enhancing preparedness for future events.



Our Opava, Czech Republic site emergency response team in action tackling a flood event, which resulted in minimal site damage

Climate Action and Resilience continued

Climate Action Across the Globe



Bulgaria

- Our Dupnitsa site launched an Energy and Carbon Reduction program in 2025 that included 21 engineering projects. These efforts upgraded and optimized key utilities through measures such as LED lighting improvements, optimized chiller and HVAC performance, enhanced insulation, steam trap replacements and extensive compressed air leak detection and recovery actions. Overall, initiatives resulted in approximately 500 tCO₂e/year in savings and improved overall systems reliability.



Israel

- Teva Tech Energy efficiency projects in 2025 included replacing a main compressor motor, adjusting the operating frequency of an air compressor, optimization of the use of dry vacuum pumps and lighting reduction.
- As part of a two-phased deal, our Kfar Saba site has signed an agreement to install a compressed natural gas onsite facility. Phase II involves connecting the supply to the national natural gas distribution pipeline. This project is expected to reduce the site's GHG emissions by an estimated 10%–15%. The transition aligns with Teva's energy-transition roadmap.



Chile

- In 2025, Laboratorio Chile advanced its sustainability strategy by operating for its first full year, a solar plant with an estimated annual generation of 1,720 MWh. Equipped with over 2,400 solar panels, spanning 13,314 m² on two solar carports and a ground-mounted photovoltaic plant, it has enabled the site to self-generate 20% of its electricity needs in 2025. This initiative resulted in a reduction of 347.79 tCO₂e emissions.



USA

- Teva USA continued its Energy Treasure Hunt program for the fourth year in line with the US Environmental Protection Agency's Energy Star program. Cross-functional teams searched facilities for ways to save energy, and sites enhanced their operational capabilities by educating employees on energy efficiency best practice. This year we replaced 30 incandescent light bulbs in our R&D facility and removed lamps from our Pick Area, saving ~9,884kWh/yr.



The Netherlands

- In 2025, our Haarlem site signed an agreement to connect it to an external waste-to-energy district heating system. Completion of the project is expected in 2027, at which point the site's natural gas consumption will be reduced by around 46%, resulting in GHG emission reductions of ~1,500 tCO₂e/year and substantially lowered site fuel cost.



Ireland

- Teva Waterford has implemented a number of decarbonization initiatives, including an energy saving program for HVAC systems, replacing air compressors with more energy-efficient models, a site energy audit and action plan.



Germany

- Teva was one of just five companies in Germany that tested the next technological step in fuel-cell trucks. The Mercedes-Benz GnH2 truck is a hydrogen fuel-cell heavy-duty vehicle designed for long-haul transport, featuring a range of over 1,000 km on a single fill of liquid hydrogen. Our fleet and transport management team's feedback will prepare the fuel-cell trucks for series production based on real-world customer requirements, including temperature-controlled pharmaceutical transport.



Teva employees in front of the Mercedes-Benz GnH2 truck in Germany

Pharmaceuticals in the Environment

We are committed to reducing the environmental impact of our business, including pharmaceuticals in the environment (PiE). PiE, including antimicrobial resistance (AMR), arise from various sources across the product life cycle. While patient use and improper disposal are primary contributors, we take action to manage and reduce impacts from our manufacturing footprint and beyond. PiE and AMR present environmental and public health challenges, for which collaboration across the value chain is needed.

Our PiE and AMR efforts traverse our value chain:

- upstream, in our extended manufacturing supply chain;
- directly in our operations, through responsible antimicrobials production; and
- downstream, through our AMR stewardship awareness campaigns with healthcare professionals (HCP) and patients on appropriate antibiotics use.

In alignment with our 2030 sustainability targets, our PiE and AMR program systematically identifies manufacturing sites for evaluation, conducts comprehensive effluent assessments and, where necessary, implements appropriate corrective and

preventive actions. This structured approach is designed to ensure that voluntary safe discharge limits¹ for antimicrobials and Priority APIs are consistently achieved. Teva defines Priority APIs as hormones, cytotoxins and active pharmaceutical ingredients included on the EU Water Framework Watch List.

Our sites have access to our wastewater discharge calculator tool, to assist them in evaluating drug substance discharge levels based on a site's product portfolio and any new product introductions.

Every Teva facility has a risk register and is obligated to recognize environmental, health and safety issues, including those related to PiE and AMR impacts.

Our Global EHS&S team supports our sites in implementing suitable mitigation and treatment options, in collaboration with our global engineering and technology teams.

Pioneering AMR Action in our Industry

Resistance to antimicrobials occurs when bacteria, and other microbes, no longer respond to antimicrobials (e.g. antibiotics) and related medicines, making infections more challenging to treat and increasing the risk and spread of disease.

AMR is an urgent health challenge – leading to more than 1.27 million deaths globally each year.² The threat of AMR means strains of bacteria resistant to antimicrobials are developing faster than new antimicrobials are being produced.

We demonstrate our transparency on AMR, by engaging with the Access to Medicine Foundation (ATMF) on their AMR Benchmark.

We are pioneers in minimizing AMR across our industry and continue to innovate with industry partners. Teva was one of the first generic companies to join the AMR Industry Alliance (AMRIA) and was a leading contributor in developing its Manufacturing Discharge Standard. We also participated in the 2025 update of this standard to more closely align it to the WHO guidance on antibiotic manufacturing discharges.



Teva employee at the Munro plant in Argentina

Since being one of the initial six companies to pilot the AMRIA discharge standard, and one of the first two companies to obtain a BSI certificate for the responsible manufacturing of an antibiotic product, we have continued to advance our progress in managing AMR manufacturing discharges across our relevant sites.

Having assessed all Teva sites handling antimicrobial drug substances since 2019, as of the end of 2025, 19 out of 26 sites had been confirmed to operate within voluntary safe discharge limits.

1 We define safe discharge levels as discharges for which we have a very high level of confidence that they will have no negative impact on the environment or public health. A site not yet achieving "safe discharge levels" does not imply the discharge is unsafe. Instead, it indicates that additional measures or assessments are required to achieve this very high level of confidence.

2 Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet; 399(10325): P629-655. DOI: [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0)

Pharmaceuticals in the Environment continued

In 2025, we undertook the following AMR-related operational initiatives to advance our efforts:

Germany and Croatia

- Our Teva sites in Ulm-Weiler, Germany and our site in Zagreb, Croatia, both passed BSI annual surveillance audits for a total of five certified antibiotic products.
- Our German site has installed an advanced wastewater treatment system, which is scheduled to begin operations in 2026. This investment will remove the need to collect antimicrobial wastewater for off-site incineration and provide the site with added operational flexibility.

India

- Our site in Goa implemented system upgrades to enable the segregation of high-API-content streams, using portable pumping units to eliminate major infrastructure works. Supplementary actions in 2026 will include installing systems to reduce effluent volumes through evaporation.

Czech Republic

- Our site in the Czech Republic has developed an on-site degradation process for cytotoxic effluents using wet oxidation technology to treat highly concentrated API streams.

Collaborating with our Supply Chain

We collaborate with our direct (Tier 1) suppliers through our Antimicrobial Supplier Survey, to help them reach safe discharge levels and adhere to AMRIA’s Manufacturing Discharge Standard.

We also engage with key industry partners, including the Pharmaceutical Supply Chain Initiative (PSCI) and the Pharmaceutical Environmental Group (PEG), to encourage more suppliers to meet industry standards. Learning from and sharing our experience will help us to drive the industry forward and reduce AMR’s extended impact throughout the supply chain.

Reducing AMR Impact Downstream and Across our Industry

Awareness and Engagement

In 2025, we took a step closer to meeting our goal of reaching 40,000 targeted healthcare professionals and 400,000 patients with educational materials on appropriate antibiotic use, supporting global AMR stewardship initiatives.

Following the success of our inaugural 2024 AMR digital awareness stewardship campaign in Germany, in 2025, we launched our second program, in Kenya (see case study to the right), to raise awareness on appropriate antibiotic prescription among general practitioners (GPs).

Case study

Digital Stewardship Initiative

Teva and Clarivate have partnered to shape a digital AMR stewardship model in Kenya, focused on education.

Teva and Clarivate have launched a new digital antimicrobial stewardship program in Kenya to reduce unnecessary or inappropriate antibiotic prescriptions, a primary driver of AMR.

Our Kenya program launched in April 2025, and engages physicians directly within their Electronic Health Record systems at the point of prescribing to support evidence-based antibiotic use from the start of treatment. In 2025, we reached around 500 GPs and 9,000 patients¹.

Through this program, select GPs in Kenya are being provided access to embedded clinical decision-support tools to access treatment guidelines in real time during patient consultations, while SMS reminders are sent to patients post-visit, reinforcing the importance of completing a prescribed course. The program aims to reach 350 GPs who serve 270,000 patients.

In December 2025, over 72% of GPs surveyed felt the alerts gave them more confidence in prescribing antibiotics appropriately. The number of GPs reporting a discussion with patients on appropriate antibiotic use rose from 50% to 55%. Almost 70% noticed a positive change in patient behavior regarding antibiotic adherence.

A preliminary review of data from the first six months of the campaign suggests a decrease in inappropriate antibiotic use for upper respiratory tract infections vs. the equivalent historical period.

These initiatives demonstrate how we are adapting targeted, digitally enabled stewardship across settings from high-resource pharmacy networks to resource-constrained clinical environments. By focusing on education, real-time decision support and measurable outcomes, we are meeting AMR’s urgency with real-world action. We will next focus on healthcare systems where AMR poses a greater threat due to limited diagnostic access, inconsistent treatment guidance and infrastructure gaps.

2025 Kenyan AMR Stewardship Project

Around **500** general practitioners reached

More than **9,000** patients reached¹ through educational messaging about appropriate antibiotics use

1 Via digital messaging to HCPs at the point of care. Not necessarily unique patients reached.

Pharmaceuticals in the Environment continued

During AMR Awareness Week in November 2025, we directed our employees to our internal AMR lobby page. Externally, our social media posts achieved a 5.8% engagement rate, with over 20,000 impressions.

Baltics

- Teva markets in the Baltics raised awareness and support for more responsible use of antibiotics through an AMR initiative with five pharmacy chains. It included an animated video to share with customers and information on AMR myths and facts.

Poland

- In 2025, Teva continued its involvement in the second run of the nationwide “World in Your Hands” campaign, launched by a Polish drug distributor to promote responsible medicine disposal. In 2025, the initiative reached over 3,000 pharmacies and 80 medical centers, offering educational materials and expert support.

Collaborating to Identify Solutions

As an AMRIA Board member, Teva collaborates with more than 100 biotech, diagnostics, generics and research-based pharmaceutical companies to spur progress in addressing AMR.

Teva is also a founding member of the AMR Action Fund, the world’s largest public-private partnership, investing in companies that are developing new antimicrobial therapies. The Fund establishes partnerships so governments can develop a sustainable antimicrobial pipeline. In 2025, we contributed USD \$579,087 to the fund, bringing our total to USD 1.7 million, with a total USD 8 million pledge over ten years (from 2021).

Reducing the Impact of Priority APIs

Beyond antimicrobials, we adopt a proactive strategy to minimize the discharge of Priority APIs, which may present environmental risk at relatively low levels. We aim to mitigate the effect of these substances on the environment from our operations and across our supply chain, demonstrating leadership and preparedness for potential upcoming PiE-related regulations.

In 2025, our responsible effluent management program for Priority APIs expanded from 10 to 19 sites manufacturing or handling these drug substances. During the year, we completed evaluations at two additional sites in the United States and Chile, both of which were confirmed to have safe discharge levels. This increased the total number of Priority API sites assessed to 11. By the end of 2025, eight of the 19 sites were confirmed to have safe discharge levels.

The 11 remaining sites will be assessed and mitigated, as necessary, so they will all achieve safe discharge levels, according to our public commitment.


In 2025, operational level initiatives to advance our priority API efforts included:

Israel

- Our Kfar Saba site evaluated two advanced wastewater treatment technologies to remove APIs in the site’s effluent and achieve safe discharge limits. Implementation of the selected technology should be implemented in 2026–2027.

Czech Republic

- Our Opava site developed an on-site degradation process for cytotoxic effluents using wet oxidation technology. The batch-mode degradation station serves the entire cytotoxic production building, treating highly concentrated API streams with a capacity of 6 m³ per day.



Employee taking a wastewater sample for analysis at the Teva site in Zagreb, Croatia

Product Sustainability

Sustainable design isn't just good for the environment – it makes business sense. We aim to reduce the environmental and carbon footprint of our products, meet regulatory and stakeholder expectations, and contribute to our Healthy Planet goals and Pivot to Growth strategy.

Teva is commencing its product sustainability journey: we are developing our Product Sustainability strategy to embed sustainability throughout the R&D decision-making process – from how we design products to how we measure and manage their impacts.

Our Product Sustainability Program

Sustainability by Design

We believe sustainability must start early in product design, where decisions have the greatest influence on a product's overall footprint. We are therefore working to establish clear sustainability principles and a structured framework to guide R&D decision-making. Our network of Product Sustainability Champions is driving this ambition forward across the organization, ensuring we optimize our choices and meet our internal targets.

Quantify Environmental Impact for Reduction

We are leveraging data to inform design decisions and enable continuous improvement. By the end of 2025, Teva had completed environmental impact assessments for five products, including Life Cycle Assessments (LCAs) and Product Carbon Footprints (PCFs), three of which were completed in 2025. As we develop our Product Sustainability strategy, we will review our current commitments and define a new target.

Green Operations

We are driving operational efficiencies by reducing packaging material intensity, lowering resource use, waste and negative environmental impacts.

Through our global sustainable packaging program, our objectives are to minimize packaging materials across plastic, paperboard and aluminum, while reducing secondary packaging weight and increasing recycled content to lower carbon emissions.



Teva employee on a packaging line in Zagreb, Croatia

Teva's global multidisciplinary Sustainability Packaging Working Group – spanning Packaging Engineering, Manufacturing Science and Technology (MS&T) and Global Portfolio – is leading a company-wide initiative to optimize packaging.

As of the end of 2025, 41 projects focused on reducing blister sizes and folding-box dimensions had been approved, with approximately 90% of these having already been implemented.

The team has successfully tested thinner cartons and materials with higher recycled content for small- and medium-sized boxes. Based on these results, and following full alignment between operations and the business, the rollout of thinner materials has begun across manufacturing sites.

5 products

assessed to date for their environmental or carbon footprint life cycle impacts

41

packaging sustainability initiatives to improve the sustainability of our product packaging

Healthy Planet: Additional Highlights



Teva employee in Germany working on a warehouse picking station

Waste and Circularity

We apply the hierarchical principles of reducing, reusing and recycling to minimize waste and harness circularity. By 2025, we decreased our overall waste generation by 38% since 2020.

Adopting and sharing best practices from Teva sites and other pharmaceutical companies can help drive continuous improvement and sustainability across operations. In 2025, we introduced a Circularity Community into our Global Environmental Sustainability Taskforce, which engages site leaders to reduce waste generation and water consumption. The Community held two sessions during 2025 on waste and water reduction technologies and packaging optimization projects.


Our sites use performance indicators to support and promote recycling and reduce waste to landfill. In 2025, we established a waste scoring indicator for sites, incentivizing them to upgrade to lower environmental impact methods. We have evaluated waste to landfill volume and composition from our sites, and plan to adopt feasible treatment methods to further reduce waste generation.

38%

decrease in overall waste generation since 2020

Where our sites cannot reuse, recycle or recover waste, our Environmental, Health and Safety Management System (EHSMS) requires them to properly manage and dispose of any residual waste. Our waste standard mandates periodic assessments for all waste vendors handling waste from Teva facilities – whether for reuse, recycling, recovery, storage or disposal. These evaluations ensure waste management contractors properly manage waste and meet our compliance requirements.

Hazardous and Non-hazardous Waste (metric tons)



Note: The slight increase in 2025 reflects network and production changes, and one-time construction-related projects.

Healthy Planet: Additional Highlights continued

Water

Our EHSMS sets our approach to water conservation and management across our operations, with more stringent requirements for those projected to be in water-stressed areas. We have reduced our total water withdrawal by 33% since 2020 and by 36% at our sites in areas projected to be in water stress¹.

As part of our ongoing actions to conserve water and transparently communicate our progress in this area, our water security score in 2025 from CDP improved to A-, our highest ever CDP water score.

Water Usage Conservation in 2025

Israel

- The Kfar Saba site is one of Teva's major water-consuming sites of those in water-stressed locations. In 2025, we commissioned a new water recycling project, the first funded by a newly-established Environmental Sustainability and Compliance Global Basket. This water recycling system, based on reverse osmosis technology, is able to recover 70%–75% of spent water from the utility plant. The expected full-year impact is 35,000m³ of water saved annually or 15% of the site's consumption. As well as reducing freshwater dependency in a water-stressed region, we aim to evaluate the system's potential deployment at other Teva sites, supporting our corporate sustainability and business objectives.

Chile

- The modernization of our purified water plant in Maipu has led to annual savings of 416.7m³ of potable water, equivalent to a sixth of a standard Olympic-sized swimming pool, through enhanced water efficiency (approximately 75%).

Malta


- We are reusing gray water for toilet flushing, as well as capturing rainwater in underground reservoirs for use with fire-sprinkler systems. We have optimized systems to use less water during sanitization processes.

Spain

- Water conservation initiatives include conductivity adjustment in the water basin of cooling towers and set point adjustment in the boiler blowdown tank. We have also installed tap aerators on bathroom faucets and flushers in the toilet cistern and reduced in-depth cleanings in the production process, which have led to a 56% reduction in water consumption per dose produced, as compared with a 2017 baseline.



Water Withdrawal (ML)



15%

of water expected to be saved annually at our Kfar Saba site due to a new water recycling system

36%

reduction in total water withdrawal since 2020 at our sites in areas projected to be in water stress¹



Teva employees in Germany

¹ 2025 data reflects an updated scope of sites based on our most recent water stress risk assessment. For further details, see pages 63–64 of the Report Disclosures.

Healthy Planet: Additional Highlights continued



Nature and Biodiversity

Loss of biodiversity and the depletion of natural resources significantly impacts economic development and human health, as they rely on functional ecosystems, according to leading experts¹. We take a science-based approach to understanding and minimizing the impact of our business on biodiversity and nature, focusing on our operations and priority raw materials. We evaluate relevant nature-related impacts and risks to establish policies and guidelines that minimize negative consequences and improve the utilization of natural resources. In 2024, we screened our sites using the WWF Biodiversity Risk Filter Suite and are assessing the results to better understand the potential impact of our operations on biodiversity.

India

- As part of our volunteering activities, 60 colleagues from Amernath R&D joined the local forest department in a seed-ball bombing activity. They spread 30,000 units, which could grow 15,000 trees, with the potential to absorb around 330 metric tons of CO₂ annually.
- Employees in Teva's Bangalore India team took part in a Hunasamarana Halli Lake Cleaning and Plantation Upkeep Drive in April 2025. Efforts focused on supporting diverse aquatic life, ensuring ecosystems remain balanced and preventing pollution: 1,000 trees were fertilized and 150kg of trash, litter and plastic were cleared.

Developing our Sustainability Culture

Teva's Go Green Together campaign encourages employees to support a healthier planet. Through offering opportunities for our employees to be directly involved in environmental actions, we are reinforcing a culture where sustainability is embedded into all aspects of our business. Building on the success of previous years, the 2025 campaign focused on volunteering and local environmental activities.

Highlights from 2025

- 6,500 employee volunteering hours, reflecting strong engagement across regions.
- Local events took place in multiple sites, including partnerships with local NGOs.
- 1,800 colleagues came together for a global "Sustainability by Design" webinar. The session explored how sustainability principles can be integrated into product development and everyday operations. Speakers shared practical examples of reducing environmental impact. The strong participation reflects growing interest among employees in learning and contributing to our sustainability goals.

>6,500

volunteering hours by Teva employees in 2025 across regions

1,800

colleagues attended our global "Sustainability by Design" webinar in 2025

1 Nature, Biodiversity and Health: An Overview of Interconnections. Source: World Health Organization, <https://iris.who.int/bitstream/handle/10665/341376/9789289055581-eng.pdf>

Healthy Business

In this Section

Ethics and Integrity	56
Sustainable Procurement	60

>99%

of our active employees completed their assigned **compliance and ethics trainings** in 2025

66%

of our significant **suppliers** (by spend) have undergone **sustainability performance evaluations**

92%

of our employees feel **comfortable reporting misconduct**, 8% higher than externally benchmarked companies



Ema in her Chemical R&D laboratory, overseeing the development of a new active pharmaceutical ingredient molecule, executing development batches in Teva's pilot plant in Zagreb, Croatia



“I’m proud to work for a company where doing what’s right truly guides us. Ethics and integrity shape my decisions every day and help us earn trust with colleagues, patients and regulators”

Ema Vukelić
Lead Pilot Engineer Scientist, Chemical R&D

[Read more on page 57](#)

Ethics and Integrity

Conducting business with integrity and transparency is non-negotiable for Teva. What we achieve is important, but how we achieve it is just as important.

We believe that operating with ethics and integrity is the right thing to do and crucial for Teva's success. We must be trusted by our patients, caregivers, healthcare professionals, customers, suppliers, investors, employees and regulatory bodies so that we can continue to deliver on our purpose.

Therefore, we uphold the highest standards of ethics and integrity and have nurtured a robust culture, where people are empowered to speak up. Each employee takes responsibility for compliance and is expected to behave ethically. Within our Leadership Principles, we state that leaders are expected to make tough choices, manage conflicts constructively and maintain our standards for ethics and integrity.

Regular training, monitoring, robust third-party due diligence and other internal processes support our approach.

To ensure ethics and integrity excellence, in 2025 we continued to enhance our risk assessment and compliance monitoring program. We are also using data, AI and analytics to identify emerging compliance risks.



Governance

The Board Compliance Committee reviews our Global Compliance and Ethics (GC&E) program, which Executive Management approves. Our Chief Compliance Officer has direct access to Executive Management and Teva's Board.


The Chief Compliance Officer leads a team of compliance professionals in managing our GC&E program. It includes third-party due diligence, trade sanctions, our Office of Business Integrity (OBI) handling Integrity Hotline calls and investigations, and data privacy topics.

Our GC&E team works collaboratively with business colleagues and legal, finance, procurement and internal audit business units. Local, regional and functional compliance professionals have responsibility for GC&E throughout Teva, and all report into our Chief Compliance Officer.

Teva's OBI is an internal, independent function responsible for managing Teva's Integrity Hotline, and objectively, confidentially and consistently addressing reports of misconduct globally. The OBI reports directly to the Chief Compliance Officer and shares its findings with the Board.

Guiding Documents

- [Teva's Code of Conduct](#)
- [Global Prevention of Corruption Policy](#)
- [Global Third-Party Due Diligence Policy](#)
- [Teva's Position on Marketing and Promotional Practices](#)
- [Teva's Integrity Hotline Complaints Procedure](#)
- [Teva's Responsible and Ethical AI Policy](#)
- [Teva's Position on Clinical Trial Ethics & Transparency Policy](#)



Teva R&D employees at our Netanya site, Israel

Ethics and Integrity continued

Progress on Targets

● Achieved ● In progress ● New target

Subtopic	Targets	Progress	Status
Ethics and Integrity			
Training	Achieve 100% ¹ completion, among active employees, for annual "Our Way" GC&E training campaigns	>99% employees trained	●
	Recertify 100% ¹ of active employees on Teva's Code of Conduct every two years (performed in 2024 and next due in 2026)	>99% employees recertified in 2024. Next planned for 2026	●
Third-Party Due Diligence	Maintain 100% evaluation ² of all submitted third-party representative (TPR) ³ business partners through Teva's TPR Due Diligence tool (RiskMate) annually	100% evaluated in 2025	●
Culture of Compliance	Meet or exceed the benchmark of high-performing ⁴ organizations for all comparable questions in Teva's Organizational Health Survey regarding compliance and ethics by 2028	Exceeded the benchmark of high-performing organizations for 1 of the 6 comparable questions ⁵	●

1 Teva's compliance training goals are 95% completion after training campaigns are assigned and 100% year-end completion (percentage calculated as average of all "Our Way" campaigns, within -1% for employees on leave).
 2 Evaluation includes both closed assessments and those that may still be in progress, require additional verifications, have had recommendations sent or need additional information.
 3 A third-party representative (TPR) is a Teva customer or vendor that connects with the government or the healthcare community on Teva's behalf or for its benefit.
 4 High-performing organizations represent the average of the top quartile of responding companies.
 5 In our baseline year of 2023, just four questions selected had comparable benchmarks. The number of comparable questions has increased from four in 2024 to six in 2025, so we've expanded the scope to include all six.



100%
 of submitted TPR³ business partners evaluated through Teva's due diligence tool

Teva employees in Israel

Ethics and Integrity continued

Our Global Compliance and Ethics Program

Teva's Global Compliance and Ethics (GC&E) Program covers policies, procedures, platforms and targeted compliance advice to drive ethical behavior and compliance with applicable laws and policies. It includes education on compliance, guidance and oversight, third-party due diligence management, compliance risk assessment and monitoring, our Code of Conduct and confidential reporting of misconduct or concerns. We continuously enhance the program through benchmarking, surveys, monitoring, assessments and analysis.

We promote the GC&E program and other compliance-related activities across our organization through leadership communications, plasma screen images, live interactive town halls, computer screensavers and newsletter articles. We also communicate policies and procedures externally, post key documents on our website and include relevant language and references in purchase orders and contracts.

Compliance and Ethics Culture

Compliance and Ethics forms part of our annual Organizational Health Survey (OHS) for Teva employees and our 2025 OHS results showed that:

- 85% of our employees gave favorable answers to questions about compliance and 77% gave favorable answers to questions about ethics; and
- 92% of our employees feel comfortable reporting misconduct – 8% higher than externally benchmarked companies.

We use these results to pinpoint specific areas that may need additional compliance and ethics support.

Read more about how we manage ethics and integrity [here](#).

92%

of our employees feel comfortable reporting misconduct

85%

of our employees answered favorably on compliance-related topics

Our Compliance and Ethics Strategy

Our strategy encompasses the following recognized standards and best practices



Ethics and Integrity continued

Upskilling Employees in Compliance and Ethics

We are committed to giving our employees the necessary knowledge, skills and resources to comply with the compliance and ethics standards described in the Teva Code of Conduct. All employees receive training on the Code biennially, which includes guidance on confidential and anonymous reporting of misconduct or concerns through our Office of Business Integrity (OBI). We expect all Teva employees to be accountable for compliance.

We also support our compliance colleagues. Throughout 2025, we:

- Provided professional development for all GC&E colleagues to strengthen their capabilities as trusted advisers, educators and business partners.
- Developed quarterly communications for compliance teams and their business partners on a range of compliance and ethics topics.

Compliance and Ethics “Our Way” Training

Teva’s annual GC&E “Our Way” training campaigns in 2025 included detailed procedures, resources and policy information on core topics, such as:



Every employee learns about our anti-corruption policies and procedures during their Prevention of Corruption training. New employees must complete foundational training on various topics, including risk prevention, insider trading, anti-bribery and anti-corruption, anti-harassment and our Code of Conduct. Supplementary (including tailored in-person) training is provided for certain higher-risk functions.

Training campaigns target relevant populations of employees based on a risk-based job classification.


In 2025

>99%

of our active employees completed their assigned compliance and ethics training

~99%

of new employees trained on our Code of Conduct in 2025



Sustainable Procurement

With a network of more than 41,000 suppliers, our influence on people, the planet and business extends well beyond our own operations. It is essential that our suppliers uphold our values and demonstrate respect for the environment and the communities we serve.

In the sustainable procurement theme of Teva’s 2025 EcoVadis assessment, we received a score of 87 (out of 100), which places us in the top 1% for our sector for the third consecutive year. This reflects our long-term commitment to responsible sourcing and contracting practices, and demonstrates our dedication to ethical supply chains, environmental stewardship and positive social impact.

Governance

The Executive Vice President, Global Operations provides executive oversight of sustainable procurement, which is led by our Chief Procurement Officer (CPO). All related commitments, strategies, policies, procedures, and activities are reviewed, reported and governed by the CPO and the Global Procurement Leadership Team.

Progress and targets for sustainability initiatives, including those related to sustainable procurement, are monitored and coordinated by our Global Environmental Sustainability Taskforce.

Guiding Documents

- [Teva’s Position on Responsible Supply Chain](#)
- [Teva’s Supplier Code of Conduct](#)
- [Teva’s Position on Human Rights](#)
- [Teva’s Conflict Minerals Policy Statement](#)

Progress on Targets

● Achieved ● In progress ● New target

Subtopic	Targets	Progress	Status
Sustainable Procurement			
Supplier Engagement and Development¹	Evaluate 95% of significant suppliers ² by spend on sustainability topics by 2030	66% ³ of significant suppliers by spend with valid assessments	●
	Achieve 70% of significant suppliers ² by spend scoring >60 points in EcoVadis by 2030	49% of significant suppliers by spend have a score >60	●

1 In 2025, the targets were revised to a spend-based approach to better align with business priorities.
 2 Significant suppliers are identified based on a defined set of criteria, including highest spend, links to antimicrobial resistance (AMR) and those targeted for sustainability initiatives based on a sustainability maturity model. These suppliers collectively represent 38% of Category 1 Scope 3 GHG emissions.
 3 Teva’s definition for valid assessment: <50pts score is valid for 12 months (annual re-assessment) and ≥50pts score is valid for 24 months (biannual re-assessment).

Sustainable Procurement continued

Collaborating for Better Procurement

A critical element in advancing sustainability as part of our Healthy Future strategy is the work of our procurement teams, which promote responsible practices in our supply chain and ensure supplier accountability.

Sustainability is not achieved in isolation and requires a holistic and collaborative approach across our value chain. We have incorporated sustainability considerations into our procurement process and how we work with suppliers and others.

Together with our suppliers and through collaborative industry initiatives, we are creating positive impact, reducing risk and securing a resilient supply chain to protect and grow our business. Our Sustainable Procurement Framework sets out our approach.



Teva warehouse employee in Osaka, Japan

Our Sustainable Procurement Framework



Integrating sustainability into our procurement process

Embedding best-in-class sustainable procurement practices into our source-to-contract process.



Internal and external engagement, education and governance

Building a sustainability training program and ensuring robust sustainability governance.



Regulatory compliance

Regulatory preparedness and implementation aligned through internal cross-functional taskforces.



Industry participation

Engaging with pharmaceutical companies to set sustainable and ethical standards.

Sustainable Procurement continued

Integrating Sustainability into our Procurement Process

We have embedded best-in-class sustainable procurement practices into all key procurement stages at Teva, including supplier selection, contracting, assessing and ongoing monitoring, to ensure our suppliers share the same values as we do.

We make our sustainability expectations clear to suppliers through our Supplier Sustainability Letter of Intent and our Supplier Code of Conduct (SCOC). They are mandatory for all our suppliers and outline our supplier expectations, our approach to a responsible supply chain and our ongoing dedication to ethical practices and environmental stewardship.

Our SCOC, which is included in our contracting templates, addresses key areas such as governance, ethics, health and safety, and environmental impact. It promotes compliance with international standards and drives continuous improvement toward ethical and sustainable business practices, and is integrated into Request for Proposal (RFP) questionnaires, contractual clauses, and Purchase Order terms and conditions for both direct and indirect purchases.

The SCOC requires suppliers to comply with all applicable laws, uphold the highest standards of integrity and prohibit corruption or bribery. It emphasizes respect for human rights, fair labor practices and non-discrimination, while ensuring safe and healthy working conditions. Suppliers are expected to minimize environmental impact, support climate initiatives and adhere to animal welfare principles. For more information, see [here](#).

Teva has continued efforts to promote equal business opportunities. Our spend with Small Medium Enterprises (SMEs) in the US was approximately \$141 million, representing 13% of our US spend.

Internal and External Engagement, Education and Governance

With more than 41,000 suppliers in our network, we focus our sustainability efforts on those suppliers which can play the greatest contribution to advancing our objectives. In 2025, we redefined our significant supplier scope to prioritize high-emitting suppliers that also drive significant Teva spend. This reduced the number of significant suppliers to 1,279 (2,245 in 2024). This targeted approach allows stronger alignment between business priorities and sustainability objectives.

We provide sustainability training and support for Teva's procurement leaders, to equip them with the knowledge and skills to engage with suppliers and drive our sustainability progress.

Our annual Sustainability Webinar for significant suppliers reinforces our SCOC and sustainability commitments, promotes the adoption of ESG assessments to evaluate sustainability practices and impact, and enhances awareness of human rights and environmental regulations. In 2025, we welcomed over 180 attendees representing 116 suppliers.

In order to monitor and advance supplier sustainability performance and practices, we use sustainability assessments conducted via the EcoVadis platform, which evaluates key themes such as environmental impact, labor and human rights, ethics and sustainable procurement practice.

Supplier Sustainability Process



Sustainable Procurement continued

In 2025, approximately 300 Teva significant suppliers were assessed or reassessed through EcoVadis, with results showing that our suppliers are becoming more advanced in sustainability areas. Since 2017 (when Teva began to use EcoVadis), our significant suppliers have shown significant progress. Specifically, the number of significant suppliers reaching advanced maturity has increased by approximately 13 times.

In 2025, we screened approximately 5,500 supplier sites (inclusive of our significant suppliers¹) on human rights and environmental risks via EiQ, a supply chain due diligence and assurance platform. In addition, for our significant suppliers, we obtain information on human rights and environmental impacts via EcoVadis.

Sustainability audits for selected suppliers are carried out under the Pharmaceutical Supply Chain Initiative (PSCI) Framework, an industry-wide collaboration aimed at advancing responsible supply-chain practices.

In 2025, Teva conducted one on-site PSCI Supplier Audit. The audit was led by a third-party PSCI-approved auditor and covered Environmental, Health and Safety topics.

Regulatory Compliance

To meet recent and emerging sustainability regulations that place supply chains at their center, our Sustainable Procurement Framework provides strong due-diligence compliance, reduces legal and reputational risk, and supports transparent reporting.

In 2025, we established compliance processes in preparation for the now delayed EU Deforestation Regulation (EUDR). Our efforts include establishing the appropriate due diligence process and raising awareness of this regulation with relevant suppliers and internal teams.

To support suppliers in managing their cash flow, we offer a Supply Chain Finance program for EcoVadis-rated suppliers to receive financing at lower rates compared with standard suppliers, fostering positive environmental and social impact within our supply chain. In 2025, 423 suppliers participated in the program, with over 30% utilizing the auto-discount mode.

Industry Participation

Collaborating with industry groups fosters greater transparency and accountability within the supply chain, strengthens supplier relationships and underscores our leadership in promoting a sustainable and ethical pharmaceutical supply chain.

Additionally, these partnerships enable us to harness innovation, and to drive continuous improvement and best practice in procurement processes, while ensuring adherence to environmental and human rights standards.

In 2025, we continued our long-term relationships with the Pharmaceutical Supply Chain Initiative (PSCI), the Pharmaceutical Environmental Group (PEG) and the Responsible Health Initiative (RHI). In partnership with RHI, we helped to educate its supplier network about the importance of collecting, identifying and sharing GHG emission metrics with member companies. RHI's supplier network grew 13% in 2025, and 56% of RHI suppliers disclosed GHG emissions metrics as of the end of 2025.



Teva CEO, Richard Francis, visiting the Ulm site in Germany

1 Significant suppliers as of 2024.

Disclosures

Disclosures

For all our data and associated sustainability information, refer to our separate Report Disclosures.

Our Report Disclosures include additional information related to:

- Global Reporting Initiative (GRI) Content Disclosures.
- Sustainability Accounting Standards Board (SASB) Disclosures.
- UN Global Compact Principles.
- Task Force on Climate-Related Financial Disclosures (TCFD).



[View our Report Disclosures](#)

About This Report

In this Section

Independent Assurance Statement	67
Cautionary Note Regarding Forward-looking Statements	72

2025 Reporting

This Report describes our key actions to advance sustainability in 2025. It complements information contained in our 2025 Annual Report on Form 10-K.

Teva has reported in accordance with the Global Reporting Initiative (GRI) Standards for the period of January 1 to December 31, 2025, as well as some 2025 initiatives that were a result of efforts in 2025. GRI reporting principles have been applied in compiling this Report. This Report fulfills our commitment to submitting an annual Communication on Progress to the United Nations Global Compact and reaffirms our commitment to embedding its principles across our business. For the sixth time, Teva is reporting per the Sustainability Accounting Standards Board (SASB) standards. As a pharmaceutical company, we have included disclosures related to the Biotechnology and Pharmaceuticals SASB industry standards. For the first time, we are also reporting with reference to the International Financial Reporting Standards (IFRS) S2 – Climate-related Disclosures, while continuing to align with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD). On a global level, reporting is carried out on a voluntary basis to address the topics important to our business and stakeholders, including those determined by our Double Materiality Assessment. In specific operations, this Report is used to comply with non-financial disclosure requirements. This Report was externally assured by DNV, as specified in the Assurance Statement based on limited assurance level, according to the International

Standard on Assurance Engagements (ISAE) 3000. For more information, please see pages 67-69. External verification of greenhouse gas (GHG) emissions data was carried out for the eleventh time. Teva 2025, Scope 1 and 2 GHG inventory has been verified in accordance with ISO 14064-3:2006 by SGS, with limited assurance. The full verification statement can be found [here](#).

Please contact Amalia Adler-Waxman, Global Head, Sustainability, with any feedback or suggestions at HealthyFuture@tevapharm.com.

Our Report has been prepared in accordance with Global Reporting Initiative (GRI) Standards and Sustainability Accounting Standards Board (SASB).

On a global level, reporting is carried out on a voluntary basis, to address the topics important to our business and stakeholders, identified by our double materiality assessment.

[Read more here](#)

Independent Limited Assurance Statement

To the Board of Directors of **Teva Pharmaceuticals Industries Ltd.**
Dvora Hanevia 124 Tel Aviv - 6944020 Israel

Statement No. DNV-2026-ASR-862455

DNV Business Assurance Italy S.r.l. ('DNV') has been commissioned by Teva Pharmaceutical Industries Ltd. (hereafter referred to as 'Teva' or 'the Company') to undertake an independent assurance of Teva's Healthy Future Report 2025 (hereafter referred to as 'Report') and selected data and information disclosed in the Report for the year ended 31st December 2025.

Assurance Approach

This assurance engagement has been carried out in accordance with DNV's VeriSustain protocol, V6.0, which is based on our professional experience and

international assurance best practice including the International Standard on Assurance Engagements (ISAE) 3000 revised – 'Assurance Engagements other than Audits and Reviews of Historical Financial Information' (revised), issued by the International Auditing and Assurance Standards Board. This standard requires that we comply with ethical requirements and plan and perform the assurance engagement to obtain limited and reasonable assurance.

DNV applies its own management standards and compliance policies for quality control, in accordance with ISO/IEC 17029:2019 – Conformity assessment, whose general principles are requirements for validation and verification bodies. Accordingly, DNV maintains a comprehensive system of quality control including documented policies and procedures regarding compliance with ethical requirements, professional standards, and applicable legal and regulatory requirements.

We performed the activities applying a limited level of assurance, as described in the following sections.

The procedures performed in a limited assurance engagement vary in nature and timing from, and are less detailed than, those undertaken during a reasonable assurance engagement, so the level of assurance obtained is substantially lower than the assurance that would have been obtained had a reasonable assurance engagement been performed. We planned and performed our work to obtain the evidence we considered sufficient to provide a basis for our conclusion, so that the risk of this conclusion being in error is reduced, but not reduced completely.

Reporting Criteria

The Report and the selected data and information have been prepared by Teva in accordance with ("Reporting Criteria"):

- GRI 1 – Foundation 2021 - Reporting Principles for reporting content and quality (Accuracy, Balance, Clarity, Comparability, Completeness, Sustainability context, Timeliness and Verifiability)
- GRI 2 – General Disclosures 2021 and GRI Topic standards in their latest applicable versions
- Point 3 of ESRS 1 (European Sustainability Reporting Standards) ("Double materiality as the basis for sustainability disclosures") and applicable Application Requirements (AR 6 – AR 16)
- Teva's Sustainability Linked Financing Framework, published on Teva website
- Methodological background for Economic impact and drug savings' impact measurements for Teva, accessible through the link available in note at page 7 of the Report
- Methodology described in the paragraph "Climate Change Disclosures" in the "Climate Action and Resilience" section in Teva's Healthy Future Report Disclosures, which is an annex to the Report Such methodology relies primarily on Task Force on Climate-Related Financial Disclosures (TCFD) recommendations.

Responsibilities of the Management of Teva and of the Assurance Providers

The Management of Teva has sole responsibility for:

- Preparing and presenting the Report;
- Designing, implementing and maintaining effective internal controls over the information and data, resulting in the preparation of the Report and the selected data and information that are free from material misstatements;
- Measuring and reporting the selected performance indicators.

DNV's responsibility is to plan and perform the work to obtain assurance about whether the Report and selected data and information have been prepared in accordance with the reporting criteria and to report to Teva in the form of an independent assurance conclusion, based on the work performed and the evidence obtained.

Our statement represents our independent opinion and is intended to inform all stakeholders. DNV was not involved in the preparation of any statements or data included in the Report except for this Independent Assurance Statement.



Independent Assurance Statement continued

Scope of Assurance

The scope of our engagement includes the assessment of the Report for adherence to GRI Reporting Principles (Accuracy, Balance, Clarity, Comparability, Completeness, Sustainability context, Timeliness and Verifiability). All GRI 2 disclosures required under an “in accordance with” reporting approach were subject to review (GRI 2-1 to GRI 2-30). We assessed the completeness, accuracy, verifiability and reliability of selected performance indicators and disclosures (‘Selected data and information’), as listed in the Appendix, which cover the following disclosure areas:

- Materiality and stakeholders
- Employee information and diversity
- Water and effluents
- Waste
- Pharmaceuticals in the environment
- Scope 3 GHG emissions
- Occupational Health & Safety
- Health Equity and Access to Medicine
- Economic contribution data
- Sustainable procurement
- Pay gap
- Business ethics and compliance
- Climate Action and Resilience.

For climate-related disclosures, the scope of assurance does not cover environmental information relating to Scope 1 and 2 GHG emissions, which have been subject to limited assurance in accordance with ISO 14064-3:2019

by SGS, as meeting the requirements of the GHG Protocol, as explained in section ‘About this Report’ of the Report.

The assessment is limited to data and information in scope within the defined reporting period. Any data outside this period is not considered within the scope of assurance. We have not performed any work, and do not express any conclusion, on any other information that may be published outside of the Report and/or on Teva’s website for the current reporting period.

DNV assumes no responsibility for any changes or updates made to the Report and to the Selected data and information after the completion of the assurance engagement.

Our Competence, Independence and Quality Control

DNV’s established policies and procedures are designed to ensure that DNV, its personnel and, where applicable, others are subject to independence requirements (including personnel of other entities of DNV) and maintain independence where required by relevant ethical requirements. This engagement work was carried out by an independent team of sustainability assurance professionals. We have no other contract with Teva.

Our multi-disciplinary team consisted of professionals with a combination of sustainability assurance experiences.

Inherent Limitations

DNV’s assurance engagements are based on the assumption that the data and information provided by the Company to us as part of our review have been provided in good faith, are true, and are free from material misstatements. Because of the selected nature (sampling) and other inherent limitations of both procedures and systems of internal control, there remains the unavoidable risk that errors or irregularities, possibly significant, may not have been detected.

The engagement excludes the sustainability management, performance, and reporting practices of the Company’s suppliers, contractors, and any third parties mentioned in the Report. We did not interview external stakeholders as part of this assurance engagement.

We understand that the reported financial data, governance and related information are based on statutory disclosures and Audited Financial Statements, which are subject to a separate independent statutory audit process.

DNV expressly disclaims any liability or co-responsibility for any decision a person or an entity may make based on this Independent Assurance Statement.

Basis of our Conclusions

As part of the assurance process, a multi-disciplinary team of assurance specialists performed assurance work at group level and for selected sites of Teva. We adopted a risk-based approach, that is, we concentrated our assurance efforts on the issues of high material relevance to the Company’s business and its key stakeholders. Our limited assurance procedures included, but were not limited to, the following activities:

- Review of the current sustainability issues that could affect Teva and are of interest to stakeholders, through a context, media and public domain review;
- Interviews with managers responsible for updating Teva’s double materiality assessment, review of the methodology applied and its results;
- Interviews with data and process owners and senior managers responsible for management of disclosures. We were free to choose interviewees and interviewed those with overall responsibility of monitoring, data consolidation and reporting of the selected data and information;
- Understanding of the key systems, processes and controls for collecting, managing, consolidating and reporting disclosures and KPIs in the Report;
- Walk-through of key data sets. Understanding and testing, on a sample basis, of the processes used to adhere to and evaluate adherence to the reporting criteria;
- Review of corporate-level data and collection of relevant raw input data to corroborate the accuracy of calculations;

Independent Assurance Statement continued

- Remote audits for Teva Group Head Office (Tel Aviv, Israel) and three sites (Kfar Saba, Israel; Debrecen, Hungary; Santiago Maipu, Chile). Sample based assessment of site-specific data disclosures was carried out. We chose the sites based on their contribution to Water & Effluents, Pharmaceuticals in the Environment, Employees' Health and Safety and Waste KPIs disclosed in Teva's Healthy Future Report, their location (including water-stressed location), and previous engagement in assurance activities.
- Review of the Report to assess its compliance with the applicable reporting criteria and to evaluate the correctness and accuracy of the information subject to our assurance procedures.

Our Conclusions

Reporting Principles

Based on the work undertaken, nothing came to our attention to suggest that the Report does not properly describe the organization's adherence to the Principles of Accuracy, Balance, Clarity, Comparability, Completeness, Sustainability context, Timeliness and Verifiability as outlined in 'Reporting Criteria' section of this Statement.

Selected Data and Information

Based on the work undertaken, nothing came to our attention to suggest that Selected data and information as described in 'Scope of assurance' are not fairly stated and have not been prepared, in all material respects, in accordance with the Reporting Criteria specified in this Statement

For and on behalf of DNV Business Assurance Italy S.r.l.
Vimercate (MB), Italy
27th April 2026

Alessia Segalini
Lead Verifier

Laura Ierardi
Reviewer

DNV Business Assurance Italy S.r.l. is part of DNV – Business Assurance, a global provider of certification, verification, assessment and training services, helping customers to build sustainable business performance. www.dnv.com

Appendix: Selected Data and Information

The scope and boundary of our work covered Selected Data and Information, which have been disclosed in the Report and in the Healthy Future Report 2025 Disclosures, which is an annex to the Report.

Materiality and stakeholders:

GRI 3-1 Process to determine material topics

GRI 3-2 List of material topics

GRI 3-3 Management of material topics

ESRS 1 - Point 3 - Double materiality as the basis for sustainability disclosures

Employee Information and Diversity:

GRI 401-1 New employee hires and employee turnover

GRI 405-1 Diversity of governance bodies and employees

Water and Effluents:

GRI 303-1 Interactions with water as a shared resource

GRI 303-2 Management of water discharge-related impacts

GRI 303-3 Water withdrawal

GRI 303-4 Water discharge

GRI 303-5 Water consumption

Waste:

GRI 306-1 Waste generation and significant waste-related impacts

GRI 306-2 Management of significant waste-related impacts

GRI 306-3 Waste generated

GRI 306-4 Waste diverted from disposal

GRI 306-5 Waste directed to disposal

Pharmaceuticals in the Environment:

Percentage of Teva sites with safe discharge levels of antimicrobials

Percentage of Teva sites with safe discharge levels of priority APIs

Health Care Professionals (HCPs) and patients reached with educational materials about appropriate antibiotic use

GHG Emissions:

GRI 305-3 Other indirect (Scope 3) GHG emissions

Health Equity and Access to Medicine:

SLB KPI 1.a: Number of regulatory submissions across six key therapeutic areas (TAs)

SLB KPI 1.b: Product volume through four access to medicine programs, including donations and social business across six key TAs

Number of beneficiaries of health system-strengthening and capacity-building initiatives

Occupational Health & Safety:

GRI 403-1 Occupational health and safety

GRI 403-2 Hazard identification, risk assessment, and incident investigation

GRI 403-3 Occupational health services

GRI 403-4 Worker participation, consultation, and communication on occupational health and safety

GRI 403-5 Worker training on occupational health and safety

GRI 403-6 Promotion of worker health

GRI 403-7 Prevention and mitigation of occupational health and safety impacts directly linked by business relationships

GRI 403-8 Workers covered by an occupational health and safety management system

GRI 403-9 Work related injuries

GRI 403-10 Work related ill health

Appendix: Selected Data and Information continued

Economic Contribution Data:

Teva's economic contribution data (direct and spillover) at the national and global level:

- Supported jobs
• Contribution to Gross Domestic Product (economic output)
• Labor income generated

Generic Drug Savings Analyses: savings attributable to Teva at the national level and global level

Sustainable Procurement:

Suppliers' data:

- Total Tier-1 suppliers
• Significant Tier-1 suppliers
• Percentage of spend on Tier-1 significant suppliers
• Number / percentage of significant suppliers with a commitment to set or approved SBTi (Science Based Targets initiative) targets
• Percentage of spend on significant suppliers with a valid EcoVadis assessment in the reporting year
• Percentage of spend on significant suppliers with a valid assessment score of over 60 in EcoVadis

Supplier screening:

- Number of suppliers screened for ESG risks in Environmental Impact Quotient (EIQ)
• Number of screened suppliers' sites for ESG risks in Environmental Impact Quotient (EIQ)

Suppliers Code of Conduct:

- Number / percentage of significant suppliers for which Teva provided training regarding the Suppliers Code of Conduct, sustainability and human rights

Assessment:

- Number / percentage of significant suppliers with valid EcoVadis assessment in the reporting year
• Number / percentage of significant suppliers with valid assessment with score >60 in EcoVadis
• Number of suppliers audited (Human Rights, Labor and Environment Audits – PSCI audits)
• Number / percentage of significant suppliers identified as having significant actual and potential negative sustainability impacts in one or more themes: Environment, Ethics, Human Rights and Labor, or Sustainable Procurement, as evaluated by EcoVadis (score < 50) in the reporting year
• Number / percentage of significant suppliers identified as having significant actual and potential negative environmental impacts (< 50 points in "Environment" EcoVadis theme)
• Number / percentage of significant suppliers identified as having significant actual and potential negative social impacts (< 50 points in "Labor & Human rights" EcoVadis theme)
• Number / percentage of significant suppliers with valid assessment that improved sustainability performance in the reporting year compared to the previous EcoVadis assessment

Pay Gap:

GRI 405-2 Ratio of basic salary and remuneration of women to men

Women pay gap (without considering level, function/profession, and location)

Business Ethics and Compliance

Percentage of active employees assigned and trained in annual "Our Way" Global Compliance & Ethics training campaign

Percentage of Foundational training completions by training assignments

Percentage of submitted Third Party Representative (TPR) business partners evaluated through Teva's Third Party due diligence tool (Risk Mate)

Number of comparable questions that appear in Teva's Organizational Health Survey related to compliance and ethics that Teva meets or exceeds the benchmark of high-performing organizations

Climate Action and Resilience

Governance

Strategy

Risk Management

Metrics & Targets

Cautionary Note Regarding Forward-looking Statements

This 2025 Healthy Future Sustainability Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. These forward-looking statements include statements concerning our plans, strategies, objectives, future performance and financial and operating targets, and any other information that is not historical information. Important factors that could cause or contribute to such differences include risks relating to:

- our ability to impact and effectively execute on our sustainability, social, economic, environment and governance-related strategies and goals; environmental risks; failure to comply with applicable environmental laws, health and safety laws and regulations worldwide; our ability to select sustainability-related disclosure frameworks that seek to align with various reporting standards, which may change from time to time; our ability to collect, measure and

report sustainability information and metrics, which is subject to evolving reporting standards; our ability to satisfy the targets set forth in our sustainability-linked senior notes, our sustainability-linked revolving credit facility and in other sustainability-linked financing instruments that we may issue; the impact of sustainability issues and other environmental risks on our business; and consequences of climate change;

- our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; concentration of our customer base and commercial alliances among our customers; competition faced by our generic medicines from other pharmaceutical companies and changes in regulatory policy that may result in additional costs and delays; delays in launches of new generic products; our ability to develop and commercialize additional pharmaceutical products in a timely manner; intense competition for our innovative medicines; our ability to achieve expected results from investments in our product pipeline; our ability to successfully execute our Pivot to Growth

strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development, to sustain and focus our portfolio of generics medicines, and to execute on our organizational transformation and to achieve expected cost savings; and the effectiveness of our patents and other measures to protect our intellectual property rights;

- our significant indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments; and our potential need to raise additional funds in the future, which may not be available on acceptable terms or at all;
- our business and operations in general, including: the impact of global economic conditions and other macroeconomic developments and the governmental and societal responses thereto, and our exposure to changes in international trade policies, including the imposition of tariffs in the jurisdictions in which we operate, and any effects of such developments on sales of our products and the pricing and availability of raw materials;

effectiveness of our optimization efforts; significant disruptions of information technology systems, including cybersecurity attacks, as well as risks and uncertainties related to the adoption of artificial intelligence technologies, and breaches of our data security; interruptions in our supply chain or problems with internal or third-party manufacturing; challenges associated with conducting business globally, including political or economic instability, prolonged government shutdowns, widespread outbreaks of major diseases and major hostilities or acts of terrorism, such as the ongoing conflicts in the Middle East and between Russia and Ukraine; our ability to attract, hire, integrate and retain highly skilled personnel; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets or business units and close or divest plants and facilities, as well as our ability to successfully and cost-effectively consummate such sales and divestitures, including our planned divestiture of our API business;

Cautionary Note Regarding Forward-looking Statements continued

- compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory requirements, the effects of regulatory uncertainty and changes and the results of increased regulatory oversight, including expenditures required to ensure compliance with research, production and quality control regulations and remedial actions taken to address product issues, such as delayed product launches, product recalls, and facility shutdowns; the effects of governmental, regulatory and civil proceedings and litigation which we are, or in the future become, party to; the effects of reforms in healthcare regulation and related reductions in pharmaceutical pricing, reimbursement and coverage, including as a result of the One Big Beautiful Bill signed into law in the U.S. in July 2025 ("OBBA"), which will likely reduce the number of insured in Medicaid and Health Insurance Exchange markets, which may alter utilization patterns and shift negotiating leverage among payors, U.S. Executive Orders issued in April and May 2025 intended to reduce the prices paid by Americans for prescription medicines, including Most-Favored-Nation pricing and related regulatory efforts; legal and regulatory actions in connection with public concern over the abuse of opioid medications; our ability to make timely payments required under our nationwide opioids settlement agreement and provide our generic version of Narcan® (naloxone hydrochloride nasal spray) in the amounts and at the times required under the terms of such agreement; scrutiny from competition and pricing authorities around the world, including our ability to comply with and operate under our deferred prosecution agreement ("DPA") with the U.S. Department of Justice ("DOJ"); potential liability for intellectual property rights infringement; significant product liability claims; claims brought by regulatory agencies; failure to comply with complex Medicare, Medicaid and other governmental programs' reporting and payment obligations; compliance with sanctions and trade control laws;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; impairments of our long-lived assets; potential significant increases in tax liabilities; the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business; and the impact of any failure to maintain effective internal control over our financial reporting; and
- other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.